Hugo_Symbol	Entrez_Gene_Id	GrCh37_Isoform	GrCh37_RefSeq	GrCh38_Isoform	GrCh38_RefSeq	# of occurrence within resources (column d_J)	OncoKB_Annotated	Is_Oncogene	Is_Tumor_Suppressor_Gene	Msk_Impact	Msk_Heme	Foundation_One	Foundation_One_Heme	Vogelstein	Sanger_Cgc(05/30/2017)	Tier_CGC(v.92)	In_CGC(v.92)	Role_In_Cancer_CGC(v.92)	In_CIViC(08_21)	Description_CIViC(08_21)	Inclusion_Level
ABL1	25	ENST00000318560	NM_005157.4	ENST00000318560	NM_005157.4	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, fusion	Yes	ABL1 is most relevant to cancer in its role in the BCR-ABL fusion protein that has become a signature of chronic myeloid leukemia (CML). Cells harboring this fusion have shown sensitivity to imatinib, greatly improving the prognostic outlook of the disease. However, additional mutations in ABL1 have been shown to confer resistance to imatinib. In these resistance cases, second-generation tyrosine kinase inhibitors such as dasatinib and nilotinib have exhibited some efficacy and are currently undergoing clinical trials for treating acquired resistance in CML.	1.0
AKT1	207	ENST00000349310	NM_001014431.1	ENST00000349310	NM_001014431.1	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes	AKT1, also referred to as protein kinase B, is a known oncogene. AKT activation relies on the PI3K pathway, and is recognized as a critical node in the pathway. The E17 hotspot is the most characterized of AKT1 mutations, and has been shown to result in activation of the protein. Mutations in AKT1 have also been shown to confer resistance to allosteric kinase inhibitors in vitro.	1.0
ALK	238	ENST00000389048	NM_004304.4	ENST00000389048	NM_004304.4	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, fusion	Yes	ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.	1.0
AMER1	139285	ENST00000330258	NM_152424.3	ENST00000374869	NM_152424.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
APC	324	ENST00000257430	NM_000038.5	ENST00000257430	NM_000038.5	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
AR	367	ENST00000374690	NM_000044.3	ENST00000374690	NM_000044.3	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes		1.0
ARID1A	8289	ENST00000324856	NM_006015.4	ENST00000324856	NM_006015.4	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG, fusion	Yes		1.0
ASXL1	171023	ENST00000375687	NM_015338.5	ENST00000375687	NM_015338.5	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
ATM	472	ENST00000278616	NM_000051.3	ENST00000278616	NM_000051.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes	Ataxia-telangiectasia (A-T) is a recessive disorder resulting from germline mutation of the A-T mutated (ATM) gene on chromosome 11q. Upon sensing double-stranded breaks (DSB), the wild-type kinase encoded by ATM initiates the DNA-damage response by phosphorylating histone H2AX and, subsequently, various other proteins, such as BRCA1 and the MRE11–RAD50–NBS1 (MRN) complex, which are recruited to the damaged site. Additionally, ATM phosphorylates p53, resulting in expression of the cyclin-dependent kinase inhibitor p21 and leading to senescence or apoptosis. Somatic variants can result in inhibition or loss of these functions and can cause resistance to therapies that rely on inducing apoptosis via DSBs. Germline variants in A-T patients result in a predisposition to cancer, most frequently hematologic or breast. PARP inhibition has been studied for its potential in treating ATM mutated breast cancer patients.	1.0
ATRX	546	ENST00000373344	NM_000489.3	ENST00000373344	NM_000489.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
AXIN1	8312	ENST00000262320	NM_003502.3	ENST00000262320	NM_003502.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	No		1.0
BAP1	8314	ENST00000460680	NM_004656.3	ENST00000460680	NM_004656.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes	BAP1 is a deubiquitylase thought to be a key regulator of many cancer-associated pathways. Germline alterations in BAP1 have been characterized as predisposing variants to familial melanocytic skin tumors. These alterations also have been linked to the development of mesothelioma, uveal melanoma, cutaneous melanoma and others. Clinically, the role of BAP1 is still being investigated. However, the development of intradermal tumors known as melanocytic BAP1-associated intradermal tumors (MBAITs) are enough for a patient to be subject to more intense surveillance to catch other malignancies as early as possible.	1.0
BCL2	596	ENST00000333681	NM_000633.2	ENST00000333681	NM_000633.2	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
BCOR	54880	ENST00000378444	NM_001123385.1	ENST00000378444	NM_001123385.1	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG, fusion	Yes		1.0
BRAF	673	ENST00000288602	NM_004333.4	ENST00000646891	NM_004333.4	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, fusion	Yes	BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer.  Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.	1.0
BRCA1	672	ENST00000357654	NM_007294.3	ENST00000357654	NM_007294.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes	BRCA1 mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. Variants that have been demonstrated to reduce the function of the protein have been shown to increase the risk for these cancers, as well as prostate and pancreatic cancer. These findings have been the impetus for the increased popularity of genetic testing of healthy individuals to assess risk. Recent studies in ovarian cancer have also demonstrated that BRCA mutation status can predict treatment response. A number of trials assessing BRCA mutation status have shown an improved response to platinum agents, and more recently has led to the FDA-approval of PARP inhibitors for BRCA-positive ovarian cancers. These studies have resulted in the Society of Gynecologic Oncology to recommend germline BRCA testing in all patients with a diagnosis of ovarian cancer.	1.0
BRCA2	675	ENST00000380152	NM_000059.3	ENST00000380152	NM_000059.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes	BRCA2 mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. Variants that have been demonstrated to reduce the function of the protein have been shown to increase the risk for these cancers, as well as prostate and pancreatic cancer. These findings have been the impetus for the increased popularity of genetic testing of healthy individuals to assess risk. Recent studies in ovarian cancer have also demonstrated that BRCA mutation status can predict treatment response. A number of trials assessing BRCA mutation status have shown an improved response to platinum agents, and more recently has led to the FDA-approval of PARP inhibitors for BRCA-positive ovarian cancers. These studies have resulted in the Society of Gynecologic Oncology to recommend germline BRCA testing in all patients with a diagnosis of ovarian cancer.	1.0
CARD11	84433	ENST00000396946	NM_032415.4	ENST00000396946	NM_032415.4	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes		1.0
CBL	867	ENST00000264033	NM_005188.3	ENST00000264033	NM_005188.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, TSG, fusion	Yes		1.0
CDC73	79577	ENST00000367435	NM_024529.4	ENST00000367435	NM_024529.4	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	No		1.0
CDH1	999	ENST00000261769	NM_004360.3	ENST00000261769	NM_004360.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
CDKN2A	1029	ENST00000304494	NM_000077.4	ENST00000304494	NM_000077.4	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes	CDKN2A loss has been shown to be a significant event in a number of cancer types. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. In majority of cases CDKN2A is inactivated by homozygous deletions. One of the mechanisms by which loss of CDKN2A can occur is by hypermethylation of the promoter region for the gene. However, the prognostic impact of promoter hypermethylation has been relatively ambiguous. Many studies have suggesting poorer prognostic outcome for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator. Additionally, CDKN2A (p16) expression is a surrogate marker for HPV infection. As such, CDKN2A expression is prognostic in Oropharyngeal and probably also non-oropharyngeal head and neck squamous cell carcinomas.	1.0
CEBPA	1050	ENST00000498907	NM_004364.3	ENST00000498907	NM_004364.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes	'AML with mutated CEBPA' is a provisional entity in the WHO classification of acute myeloid leukemia (AML) and is recommended to be tested for in patients with AML. CEBPA mutations are particularly associated with cytogenetically normal AML (CN-AML). CEBPA is an intronless gene that is required for granulocyte formation in mice. N-terminal nonsense mutations result in a dominant negative C/EBP-alpha protein while C-terminal mutations reduce the DNA-binding potential of this transcription factor. CEBPA mutations are associated with a favorable prognosis, however, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.	1.0
CIC	23152	ENST00000575354	NM_015125.3	ENST00000575354	NM_015125.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, TSG, fusion	Yes		1.0
CREBBP	1387	ENST00000262367	NM_004380.2	ENST00000262367	NM_004380.2	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, TSG, fusion	Yes		1.0
CTNNB1	1499	ENST00000349496	NM_001904.3	ENST00000349496	NM_001904.3	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
DAXX	1616	ENST00000374542	NM_001141970.1	ENST00000266000	NM_001141970.1	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, TSG	No		1.0
DNMT3A	1788	ENST00000264709	NM_022552.4	ENST00000264709	NM_022552.4	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes	DNMT3A is one of several epigenetic modifiers identified as recurrently mutated in acute myeloid leukemia (AML). DNMT3A mutations are associated with cytogenetically normal AML. In vitro experiments indicate that the R882H mutation acts in a dominant negative manner to disrupt the de novo methyltransferase activity of wildtype homotetramers. AML patient bone marrow harboring R882 mutations were similarly demonstrated to be hypomethylated compared to patients with wildtype DNMT3A. These studies also indicated that non-R882 DNMT3A mutations may act in a functionally distinct manner from R882 mutations. Alternative mechanisms indicate independent prognostic outcomes and treatment protocols may need to be considered for these two classes of DNMT3A mutations.	1.0
EGFR	1956	ENST00000275493	NM_005228.3	ENST00000275493	NM_005228.3	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes	EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer.  Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).	1.0
EP300	2033	ENST00000263253	NM_001429.3	ENST00000263253	NM_001429.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG, fusion	Yes		1.0
ERBB2	2064	ENST00000269571	NM_004448.2	ENST00000269571	NM_004448.2	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, fusion	Yes	ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.	1.0
EZH2	2146	ENST00000320356	NM_004456.4	ENST00000320356	NM_004456.4	7.0	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, TSG	Yes		1.0
FBXW7	55294	ENST00000281708	NM_033632.3	ENST00000281708	NM_033632.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
FGFR2	2263	ENST00000358487	NM_000141.4	ENST00000358487	NM_000141.4	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, fusion	Yes	The FGFR proteins are involved in a wide array of pathways known to play a signficant role in cancer. Activation of these receptors can lead to activation of the RAS-MAPK pathway and the PI3K-AKT pathway, among others. The mechanisms by which FGFR can be misregulated vary between cancers. Amplification of the receptors has been observed in lung and breast cancers, coding mutations and deletions have been seen in many cancers, and more recently, FGFR fusions that lead to pathway actiation have been demonstrated to have oncogenic potential across multiple cancer types. The targeted therapeutics ponatinib, dovitinib and pazopanib have seen success in treating over-active FGFR signalling, prompting use of diagnostic sequencing targeting the FGFR genes, especially in lung cancer patients.	1.0
FGFR3	2261	ENST00000260795	NM_000142.4	ENST00000440486	NM_000142.4	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, fusion	Yes	The FGFR proteins are involved in a wide array of pathways known to play a signficant role in cancer. Activation of these receptors can lead to activation of the RAS-MAPK pathway and the PI3K-AKT pathway, among others. The mechanisms by which FGFR can be misregulated vary between cancers. Amplification of the receptors has been observed in lung and breast cancers, coding mutations and deletions have been seen in many cancers, and more recently, FGFR fusions that lead to pathway actiation have been demonstrated to have oncogenic potential across multiple cancer types. The targeted therapeutics ponatinib, dovitinib and pazopanib have seen success in treating over-active FGFR signalling, prompting use of diagnostic sequencing targeting the FGFR genes, especially in lung cancer patients.	1.0
FLT3	2322	ENST00000241453	NM_004119.2	ENST00000241453	NM_004119.2	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes	FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.	1.0
FOXL2	668	ENST00000330315	NM_023067.3	ENST00000648323	NM_023067.3	7.0	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, TSG	Yes		1.0
GATA3	2625	ENST00000346208	NM_002051.2	ENST00000346208	NM_002051.2	7.0	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, TSG	No		1.0
GNA11	2767	ENST00000078429	NM_002067.2	ENST00000078429	NM_002067.2	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes		1.0
GNAQ	2776	ENST00000286548	NM_002072.3	ENST00000286548	NM_002072.3	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes		1.0
GNAS	2778	ENST00000371085	NM_000516.4	ENST00000371085	NM_000516.4	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes		1.0
HNF1A	6927	ENST00000257555	NM_000545.5	ENST00000257555	NM_000545.5	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	No		1.0
HRAS	3265	ENST00000451590	NM_005343.2	ENST00000451590	NM_005343.2	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes		1.0
IDH1	3417	ENST00000345146	NM_005896.2	ENST00000345146	NM_005896.2	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes	IDH1 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types. The most frequent mutations involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic enzyme activity. The implications of mutations in this gene vary greatly by cancer type. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 mutations have been associated with worse outcome, shorter overall survival, and normal karyotype. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Unlike the association with cytogenetically normal AML, in glioblastoma, IDH1 mutations have been associated with specific cytogenetic abnormalities, 1p and 19q deletions.	1.0
IDH2	3418	ENST00000330062	NM_002168.2	ENST00000330062	NM_002168.2	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes	IDH2 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types. The most frequent mutations involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic enzyme activity. Although IDH2 (R172) mutations are associated with poorer overall prognosis in AML patients, its utility as a prognostic marker in MDS is still under debate. Additionally, IDH2 (R140) has been associated with improved overall survival in AML. IDH2 mutations have been associated with improved prognosis in gliomas.	1.0
JAK1	3716	ENST00000342505	NM_002227.2	ENST00000342505	NM_002227.2	7.0	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, TSG	Yes		1.0
JAK2	3717	ENST00000381652	NM_004972.3	ENST00000381652	NM_004972.3	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, fusion	Yes	JAK2 is a kinase that is misregulated or mutated in a number of myeloproliferative diseases and cancers. The mutation V617F is the most clinically relevant variant, and is seen in around half of myeloproliferative disorders. The variant is a known activating mutation, and activated JAK2 is sufficient to drive myeloproliferative disorders in mouse models. V617F, while most recurrent, is not the only mechanism by which JAK2 can be activated in patients. JAK2 is now one of the first diagnostic markers tested upon diagnosis with a myeloproliferative disorder.	1.0
JAK3	3718	ENST00000458235	NM_000215.3	ENST00000458235	NM_000215.3	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes		1.0
KDM5C	8242	ENST00000375401	NM_004187.3	ENST00000375401	NM_004187.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
KDM6A	7403	ENST00000377967	NM_021140.2	ENST00000377967	NM_021140.2	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, TSG	Yes		1.0
KIT	3815	ENST00000288135	NM_000222.2	ENST00000288135	NM_000222.2	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes	c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.	1.0
KMT2D	8085	ENST00000301067	NM_003482.3	ENST00000301067	NM_003482.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, TSG	Yes		1.0
KRAS	3845	ENST00000311936	NM_004985.3	ENST00000311936	NM_004985.3	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes	Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.	1.0
MAP2K1	5604	ENST00000307102	NM_002755.3	ENST00000307102	NM_002755.3	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes	MAP2K1 is a dual-specificity kinase known for it's involvement in the ERK pathway by activation of ERK1 and ERK2. MAP2K1 activating mutations have been observed in a number of cancers including ovarian,  melanoma and lung. These activating mutations are generally found in the N-terminal negative regulatory region or the ATP-binding region of the N-terminal lobe.  Inhibitors of MEK genes have been shown to inhibit tumor growth in these cases.	1.0
MAP3K1	4214	ENST00000399503	NM_005921.1	ENST00000399503	NM_005921.1	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, TSG	No		1.0
MED12	9968	ENST00000374080	NM_005120.2	ENST00000374080	NM_005120.2	7.0	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	No		1.0
MEN1	4221	ENST00000312049	NM_130799.2	ENST00000312049	NM_130799.2	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
MET	4233	ENST00000397752	NM_000245.2	ENST00000397752	NM_000245.2	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes	"Mesenchymal Epithelial Transition MET is a prototypical receptor tyrosine kinase. Its ligand is Hepatocyte Growth Factor (HGF). MET alterations are drivers of human cancer.  Amplification and resulting overexpression has been reported in several cancers, and make the receptor's activity independent of HGF. Gene fusions also decouple kinase activity from the cell membrane and render it constitutively active.  Finally, exclusion of the juxtamembrane (JM) domain of the kinase by ""skipping"" of exon 14 activates the kinase."	1.0
MLH1	4292	ENST00000231790	NM_000249.3	ENST00000231790	NM_000249.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes	MLH1 is a tumor suppressor gene involved in DNA mismatch repair. Germline mutations in this gene are known to cause Lynch syndrome. The most common malignancies in Lynch syndrome are colorectal and endometrial carcinomas. In addition to germline mutations, somatic mutations in this gene have been described in colorectal and endometrial cancers.	1.0
MPL	4352	ENST00000372470	NM_005373.2	ENST00000372470	NM_005373.2	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes		1.0
MSH2	4436	ENST00000233146	NM_000251.2	ENST00000233146	NM_000251.2	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
MSH6	2956	ENST00000234420	NM_000179.2	ENST00000234420	NM_000179.2	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
MYD88	4615	ENST00000396334	NM_002468.4	ENST00000396334	NM_002468.4	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes		1.0
NF1	4763	ENST00000356175	NM_000267.3	ENST00000356175	NM_000267.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG, fusion	Yes		1.0
NF2	4771	ENST00000338641	NM_000268.3	ENST00000338641	NM_000268.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
NFE2L2	4780	ENST00000397062	NM_006164.4	ENST00000397062	NM_006164.4	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, TSG	Yes		1.0
NOTCH1	4851	ENST00000277541	NM_017617.3	ENST00000651671	NM_017617.3	7.0	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, TSG, fusion	Yes	NOTCH1 is one of four known genes encoding the NOTCH family of proteins, a group of receptors involved in the Notch signaling pathway. NOTCH proteins are characterized by N-terminal EGF-like repeats followed by LNR domains which form a complex with ligands to prevent signaling. The Notch signaling pathway is involved in processes related to cell fate specification, differentiation, proliferation, and survival. Activation of Notch has been shown to be correlative with mammary tumorgenesis in mice and increased expression of Notch receptors has been observed in a variety of cancer types including cervical, colon, head and neck, lung, renal, pancreatic, leukemia, and breast cancer. A number of treatment modalities have been explored related to Notch inhibition especially in breast cancer with mixed results.	1.0
NOTCH2	4853	ENST00000256646	NM_024408.3	ENST00000256646	NM_024408.3	7.0	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, TSG	No		1.0
NPM1	4869	ENST00000296930	NM_002520.6	ENST00000296930	NM_002520.6	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, fusion	Yes	AML with mutated NPM1 is a provisional entity in the WHO classification of AML and is recommended to be tested in patients with cytogenetically normal AML (CN-AML). FLT3 mutations should be evaluated concurrently as they have prognostic consequences. NPM1 mutations are concentrated in exon 12, most frequently W288fs which results in cytoplasmic sequestration of the protein. Exon 12 NPM1 mutations in the absence of FLT3-ITD are associated with good prognostic outcomes. Mice expressing the Npm1-W288fs mutation develop myeloproliferative neoplasms but not overt leukemia, indicating it may require additional mutations to promote leukemic development.	1.0
NRAS	4893	ENST00000369535	NM_002524.4	ENST00000369535	NM_002524.4	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes	Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.	1.0
PAX5	5079	ENST00000358127	NM_016734.2	ENST00000358127	NM_016734.2	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, TSG, fusion	Yes		1.0
PBRM1	55193	ENST00000394830	NM_018313.4	ENST00000394830	NM_018313.4	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
PDGFRA	5156	ENST00000257290	NM_006206.4	ENST00000257290	NM_006206.4	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, fusion	Yes	Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.	1.0
PIK3CA	5290	ENST00000263967	NM_006218.2	ENST00000263967	NM_006218.2	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes	PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.	1.0
PIK3R1	5295	ENST00000274335	NM_181523.2	ENST00000521381	NM_181523.2	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
PPP2R1A	5518	ENST00000322088	NM_014225.5	ENST00000322088	NM_014225.5	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
PRDM1	639	ENST00000369096	NM_001198.3	ENST00000369096	NM_001198.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
PTCH1	5727	ENST00000331920	NM_000264.3	ENST00000331920	NM_000264.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
PTEN	5728	ENST00000371953	NM_000314.4	ENST00000371953	NM_000314.4	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes	PTEN is a multi-functional tumor suppressor that is very commonly lost in human cancer. Observed in prostate cancer, glioblastoma, endometrial, lung and breast cancer to varying degrees. Up to 70% of prostate cancer patients have been observed to have loss of expression of the gene. It is a part of the PI3K/AKT/mTOR pathway and mTOR inhibitors have been relatively ineffective in treating patients with PTEN loss. New appoaches using microRNAs are currently being investigated.	1.0
PTPN11	5781	ENST00000351677	NM_002834.3	ENST00000351677	NM_002834.3	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes		1.0
RB1	5925	ENST00000267163	NM_000321.2	ENST00000267163	NM_000321.2	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
RET	5979	ENST00000355710	NM_020975.4	ENST00000355710	NM_020975.4	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, fusion	Yes	RET mutations and the RET fusion RET-PTC lead to activation of this tyrosine kinase receptor and are associated with thyroid cancers. RET point mutations are the most common mutations identified in medullary thyroid cancer (MTC) with germline and somatic mutations in RET associated with hereditary and sporadic forms, respectively. The most common somatic form mutation is M918T (exon 16) and a variety of other mutations effecting exons 10, 11 and 15 have been described. The prognostic significance of these mutations have been hotly debated in the field, however, data suggests that some RET mutation may confer drug resistence. No RET-specific agents are currently clinically available but several promiscuous kinase inhibitors that target RET, among others, have been approved for MTC treatment.	1.0
RNF43	54894	ENST00000407977	NM_017763.4	ENST00000407977	NM_017763.4	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	No		1.0
SETD2	29072	ENST00000409792	NM_014159.6	ENST00000409792	NM_014159.6	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	No		1.0
SF3B1	23451	ENST00000335508	NM_012433.2	ENST00000335508	NM_012433.2	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes	SF3B1 mutations have been described in several myeloid malignancies, predominantly myelodysplastic syndromes (MDS), as well as other hematologic malignancies, breast cancer, and uveal melanoma (UM). SF3B1 is one of several genes involved in RNA splicing that has been identified as recurrently mutated in MDS and other malignanices. The mutations affecting SF3B1 are typically heterozygous, point mutations suspected to be functionally deleterious with R625 and K700E described as a major mutation hotspots. MDS patients with SF3B1 mutations have been reported to have better overall and event-free survival than their wildtype counterparts. Additionally, these mutations are highly associated with subtypes of MDS characterized by ringed sideroblasts (refractory anemia with ringed sideroblasts and refractory cytopenia with multilineage dysplasia and ring sideroblasts). In UM patients, SF3B1 mutations have been reported to be associated with chromosome 3 disomy, which defines a subgroup with low risk of metastasis.	1.0
SMAD2	4087	ENST00000262160	NM_001003652.3	ENST00000262160	NM_001003652.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	No		1.0
SMAD4	4089	ENST00000342988	NM_005359.5	ENST00000342988	NM_005359.5	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
SMARCA4	6597	ENST00000358026	NM_001128849.1	ENST00000646693	NM_001128849.1	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
SMARCB1	6598	ENST00000263121	NM_003073.3	ENST00000618915	NM_003073.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
SMO	6608	ENST00000249373	NM_005631.4	ENST00000249373	NM_005631.4	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes		1.0
SOCS1	8651	ENST00000332029	NM_003745.1	ENST00000332029	NM_003745.1	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	No		1.0
SPOP	8405	ENST00000347630	NM_001007228.1	ENST00000347630	NM_001007228.1	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
STAG2	10735	ENST00000218089	NM_001042749.1	ENST00000218089	NM_001042749.1	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
STK11	6794	ENST00000326873	NM_000455.4	ENST00000326873	NM_000455.4	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
TET2	54790	ENST00000380013	NM_001127208.2	ENST00000380013	NM_001127208.2	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
TNFAIP3	7128	ENST00000237289	NM_006290.3	ENST00000237289	NM_006290.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	No		1.0
TP53	7157	ENST00000269305	NM_000546.5	ENST00000269305	NM_000546.5	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, TSG, fusion	Yes	TP53 mutations are universal across cancer types. The loss of a tumor suppressor is most often through large deleterious events, such as frameshift mutations, or premature stop codons. In TP53 however, many of the observed mutations in cancer are found to be single nucleotide missense variants. These variants are broadly distributed throughout the gene, but with the majority localizing in the DNA binding domain. There is no single hotspot in the DNA binding domain, but a majority of mutations occur in amino acid positions 175, 245, 248, 273, and 282 (NM_000546) (Olivier et al., 2010). To fulfill its proper biological function four TP53 polypeptides must form a tetramer which functions as a transcription factor, therefore even if one out of four polypeptides has inactivating mutation it may lead to dominant negative phenotype of variable degree. While a large proportion of cancer genomics research is focused on somatic variants, TP53 is also of note in the germline. Germline TP53 mutations are the hallmark of Li-Fraumeni syndrome, and many (both germline and somatic) variants have been found to have a prognostic impact on patient outcomes. The significance of many polymorphisms for susceptibility and prognosis of disease is still very much up for debate.	1.0
TSC1	7248	ENST00000298552	NM_000368.4	ENST00000298552	NM_000368.4	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
U2AF1	7307	ENST00000291552	NM_006758.2	ENST00000291552	NM_006758.2	7.0	Yes	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene	Yes	U2AF1 is one of several spliceosome complex genes frequently mutated in a variety of hematologic malignancies, particularly de novo myelodysplastic syndromes (MDS), as well as solid tumors such as lung and pancreatic cancers. Two hotspot mutations (S34 and Q157) occur within the two zinc-finger domains of the U2AF1 protein. These mutations have been associated with altered splicing patterns in vitro and in vivo. U2AF1 mutations in MDS have been associated with an increased risk of transformation to secondary acute myeloid leukemia, however, the impact of these mutations on overall survival has been an area of debate.	1.0
VHL	7428	ENST00000256474	NM_000551.3	ENST00000256474	NM_000551.3	7.0	Yes	No	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	TSG	Yes	Von Hippel-Lindau (VHL) disease is characterized by heterozygous germline mutation in VHL gene on chromosome 3p. Patients are predisposed to developing hemangioblastomas of the brain, spinal cord, and retina; renal cysts and clear cell renal cell carcinoma; pheochromocytoma, pancreatic cysts and neuroendocrine tumors; endolymphatic sac tumors; and epididymal and broad ligament cysts. Cerebellar hemangioblastomas may be associated with headache, vomiting, gait disturbances, or ataxia. Spinal hemangioblastomas and related syrinx usually present with pain. Sensory and motor loss may develop with cord compression. Retinal hemangioblastomas may be the initial manifestation of VHL disease and can cause vision loss. Renal cell carcinoma occurs in about 70% of individuals with VHL and is the leading cause of mortality. Pheochromocytomas can be asymptomatic but may cause sustained or episodic hypertension. Pancreatic lesions often remain asymptomatic and rarely cause endocrine or exocrine insufficiency. Endolymphatic sac tumors can cause hearing loss of varying severity, which can be a presenting symptom. Cystadenomas of the epididymis are relatively common. They rarely cause problems, unless bilateral, in which case they may result in infertility.  The VHL gene product encodes pVHL, which binds to elongin C, elongin B, cullin-2 and Rbx1. This complex catalyzes the polyubiquitinylation of specific proteins and targets them for degradation by proteosomes. For example, under normoxic conditions, hydroxylated hypoxia-inducble factor alpha subunits (HIFα) binds pVHL targets HIFα for degradation. Under hypoxic conditions, HIF1α is not hydroxylated, pVHL does not bind, and HIF1α subunits accumulate. HIF1α forms heterodimers with HIF1β and activates transcription of a variety of hypoxia-inducible genes (i.e., VEGF, EPO, TGFα, PDGFβ). Likewise, when pVHL is absent or mutated, HIF1α subunits accumulate, resulting in cell proliferation and the neovascularization of tumors characteristic of VHL disease.  Pathogenic variants in VHL either prevent its expression (i.e., deletions, frameshifts, nonsense mutations, and splice site mutations) or lead to the expression of an abnormal protein (i.e., missense mutations). Missense mutations that destabilize packing of the alpha-helical domains, decrease the stability of the alpha-beta domain interface, interfere with binding of elongin C and HIF1α, or disrupt hydrophobic core residues result in loss of HIF regulation and are more likely to result in VHL type 1 (no predisposition to pheochromocytoma).  Missense mutations that result in pVHL that is normal with respect to HIF regulation are more likely to be associated with VHL with clinical pheochromocytoma.   Acquired somatic pathogenic variants in VHL may give rise to sporadic VHL-type tumors (i.e., clear cell RCC and hemangioblastoma) without other associated tumors characteristic of the hereditary disease. It should be noted that >90% of the most common form of kidney cancer (clear cell renal cell carcinoma) are associated with bi-allelic somatic mutation in the VHL gene, and is the rationale for the anti-angiogenic therapy for RCC patients.	1.0
WT1	7490	ENST00000332351	NM_024426.4	ENST00000452863	NM_024426.4	7.0	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	1.0	Yes	oncogene, TSG, fusion	Yes	WT1 is a tumor suppressor gene associated with the development of Wilms' Tumor, from which it was named. Mutations in exon 7 and 9 of WT1 have been recurrently identified in acute myeloid leukemia and associated with poorer prognosis and chemotherapy resistance.	1.0
AKT2	208	ENST00000392038	NM_001626.4	ENST00000392038	NM_001626.4	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
ARID2	196528	ENST00000334344	NM_152641.2	ENST00000334344	NM_152641.2	6.0	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
ATR	545	ENST00000350721	NM_001184.3	ENST00000350721	NM_001184.3	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	Yes		1.0
B2M	567	ENST00000558401	NM_004048.2	ENST00000559916	NM_004048.2	6.0	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
BARD1	580	ENST00000260947	NM_000465.2	ENST00000260947	NM_000465.2	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	Yes		1.0
BCL6	604	ENST00000232014	NM_001706.4	ENST00000232014	NM_001706.4	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
BRD4	23476	ENST00000263377	NM_058243.2	ENST00000263377	NM_058243.2	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
BRIP1	83990	ENST00000259008	NM_032043.2	ENST00000259008	NM_032043.2	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	No		1.0
BTK	695	ENST00000308731	NM_000061.2	ENST00000308731	NM_000061.2	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, TSG	Yes		1.0
CALR	811	ENST00000316448	NM_004343.3	ENST00000316448	NM_004343.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
CASP8	841	ENST00000358485	NM_001080125.1	ENST00000358485	NM_001080125.1	6.0	Yes	No	Yes	Yes	Yes	Yes	No	Yes	Yes	1.0	Yes	TSG	Yes		1.0
CBFB	865	ENST00000412916	NM_022845.2	ENST00000412916	NM_022845.2	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG, fusion	Yes	CBFB has been shown to be mutated in estrogen receptor positive breast cancer, although the significance of many of these mutations is yet to be determined. The CBFB-MYH11 fusion is a commonly accepted marker of favorable prognosis in acute myeloid leukemia.	1.0
CCND1	595	ENST00000227507	NM_053056.2	ENST00000227507	NM_053056.2	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins, and the cyclin-dependent kinases (CDK's) they activate, have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. While Cyclin D2 has only been found to be significantly deregulated in glioma, Cyclin D1 seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, but currently there are no FDA-approved targeted therapies.	1.0
CCND2	894	ENST00000261254	NM_001759.3	ENST00000261254	NM_001759.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. While Cyclin D2 has only been found to be significantly deregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	1.0
CCND3	896	ENST00000372991	NM_001760.3	ENST00000372991	NM_001760.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. Cyclin D3 loss has been reported in T-ALL, a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. In a mouse study, the targeted therapeutic palbociclib significantly increased the median survival of the cyclin D3 knockouts.	1.0
CCNE1	898	ENST00000262643	NM_001238.2	ENST00000262643	NM_001238.2	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes	Cyclin E, while currenly not as widely implicated as its cyclin D counterparts, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, have been shown to lead to poorer prognosis in gastic carcinoma, and these measurements are correlated with later stage disease. In lung cancer, neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their more lowly expressed counterparts.	1.0
CD274	29126	ENST00000381577	NM_014143.3	ENST00000381577	NM_014143.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG, fusion	Yes	CD274, also commonly referred to as PDL1, is a ligand that binds with the receptor PD1, commonly found on T-cells, and acts to block T-cell activation. PD1 expression has been observed in a variety of cancers including melanoma and non-small cell lung cancer. The interaction of PD1/PDL1 is hypothesized to be a possible mechanism for the tumor to escape immune response. A number of checkpoint blockade inhibitors including pembrolizumab and nivolumab have been developed that target the PD1/PDL1 interaction in order to allow T-cells to recognize tumor cells without being deactivated by the tumor.	1.0
CD79A	973	ENST00000221972	NM_001783.3	ENST00000221972	NM_001783.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	No		1.0
CD79B	974	ENST00000392795	NM_001039933.1	ENST00000392795	NM_001039933.1	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
CDK12	51755	ENST00000447079	NM_016507.2	ENST00000447079	NM_016507.2	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	Yes		1.0
CDK4	1019	ENST00000257904	NM_000075.3	ENST00000257904	NM_000075.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes	CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.	1.0
CDK6	1021	ENST00000265734	NM_001145306.1	ENST00000265734	NM_001145306.1	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes	CDK6, along with its partner CDK4, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.	1.0
CDKN1B	1027	ENST00000228872	NM_004064.3	ENST00000228872	NM_004064.3	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	Yes		1.0
CDKN2C	1031	ENST00000262662	NM_078626.2	ENST00000262662	NM_078626.2	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	No		1.0
CHEK2	11200	ENST00000328354	NM_007194.3	ENST00000404276	NM_007194.3	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	Yes		1.0
CRLF2	64109	ENST00000381566	NM_022148.2	ENST00000381566	NM_022148.2	6.0	Yes	Yes	No	Yes	Yes	No	Yes	Yes	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
CSF1R	1436	ENST00000286301	NM_005211.3	ENST00000286301	NM_005211.3	6.0	Yes	No	No	Yes	Yes	Yes	Yes	Yes	No	2.0	Yes	oncogene	Yes		1.0
CSF3R	1441	ENST00000361632	NM_000760.3	ENST00000361632	NM_000760.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
CTCF	10664	ENST00000264010	NM_006565.3	ENST00000264010	NM_006565.3	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	Yes		1.0
CXCR4	7852	ENST00000241393	NM_003467.2	ENST00000241393	NM_003467.2	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
DDR2	4921	ENST00000367921	NM_006182.2	ENST00000367921	NM_006182.2	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
ERBB3	2065	ENST00000267101	NM_001982.3	ENST00000267101	NM_001982.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
ERBB4	2066	ENST00000342788	NM_005235.2	ENST00000342788	NM_005235.2	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, TSG	Yes	ErbB4 (HER4) is one of the four members in the EGFR subfamily of receptor tyrosine kinases. Ligands include EGF, epiregulin, betacellulin and the neuregulins (Sundvall et. al.). Of these, NRG3 and NRG4 exclusively bind HER4 (Hynes et. al.).  Mutations in ERBB4 have been identified in various cancer types including melanoma, lung adenocarcinoma and medulloblastoma. A therapeutic value of these aberrations still remains unknown (Arteaga et. al.).	1.0
ERG	2078	ENST00000288319	NM_182918.3	ENST00000288319	NM_182918.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
ESR1	2099	ENST00000206249	NM_001122740.1	ENST00000206249	NM_001122740.1	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	Yes	ESR1 has been a focus in breast cancer for quite some time, but is also clinically relevant in endometrial, ovarian and other cancer types. The identification of ER-positive breast cancers that are resistant to hormone therapy have inspired clinical sequencing efforts to shed light on the mechanisms of this resistance. A number of mutations in the ligand binding domain of ESR1 have been implicated in hormone resistance and anti-estrogen therapies. These observations have spurred efforts to develop therapeutics that stimulate ESR1 protein degradation (e.g. Fulvestrant), rather than acting as a small molecule antagonist. These agents are currently in clinical trials and have seen some success.	1.0
ETV6	2120	ENST00000396373	NM_001987.4	ENST00000396373	NM_001987.4	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG, fusion	Yes		1.0
FANCA	2175	ENST00000389301	NM_000135.2	ENST00000389301	NM_000135.2	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	Yes		1.0
FANCC	2176	ENST00000289081	NM_000136.2	ENST00000289081	NM_000136.2	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	Yes		1.0
FGFR1	2260	ENST00000425967	NM_001174067.1	ENST00000425967	NM_001174067.1	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes	FGFR1 is a member of the Fibroblast Growth Factor family, comprising of 4 receptors and 18 Ligands.  FGFR1 signalling downstream functions mainly via PI3K and MAPK pathways (Turner et. al.). Several ways of involvement of FGFR1 in cancer have been proposed: auto- and paracrine activation, amplification and overexpression (Marshall et. al,  Weiss et. al.,  Cheng et. al.). Especially amplification of FGFR1 in lung cancer is an emerging treatment target with clinical studies currently ongoing (e.g. NCT01004224). However, FGFR1 amplification does not always correlate with protein expression and predictive biomarkers still remain to be defined in clinic (von Mässenhausen et. al.). Mutation of FGFR1 seems to be less common, but has been described in glioblastoma, pilocytic astrocytomas and Ewing's sarcoma (Rand et. al., Jones et. al., Agelopoulos et. al.).	1.0
FGFR4	2264	ENST00000292408	NM_213647.1	ENST00000292408	NM_213647.1	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
FLCN	201163	ENST00000285071	NM_144997.5	ENST00000285071	NM_144997.5	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	Yes		1.0
FUBP1	8880	ENST00000370768	NM_003902.3	ENST00000370768	NM_003902.3	6.0	Yes	No	Yes	Yes	Yes	Yes	No	Yes	Yes	1.0	Yes	oncogene	Yes		1.0
GATA1	2623	ENST00000376670	NM_002049.3	ENST00000376670	NM_002049.3	6.0	Yes	No	No	Yes	Yes	No	Yes	Yes	Yes	1.0	Yes	oncogene, TSG	Yes		1.0
GATA2	2624	ENST00000341105	NM_032638.4	ENST00000341105	NM_032638.4	6.0	Yes	Yes	No	Yes	Yes	No	Yes	Yes	Yes	1.0	Yes	oncogene	Yes	GATA2 is a transcription factor involved in stem cell maintenance with key roles in hematopoietic development. GATA2 mutations are associated with a variety of inherited and acquired immune disorders including myelodysplastic syndrome and acute myeloid leukemia. In addition to a role in hematopoiesis, the maintenance GATA2 expression has been implicated as a requirement in KRAS-driven non-small cell lung cancer. Preclinical models have indicated therapeutic benefit from targeting GATA2-mediated pathways in the context of KRAS-driven NSCLC.	1.0
H3-3A	3020	ENST00000366813	NM_002107.4	ENST00000366815	NM_002107.4	6.0	Yes	Yes	No	Yes	Yes	Yes	No	Yes	Yes		No		Yes		2.0
H3C2	8358	ENST00000244661	NM_003537.3	ENST00000621411	NM_003537.3	6.0	Yes	No	No	Yes	Yes	No	Yes	Yes	Yes		No		Yes		2.0
IKZF1	10320	ENST00000331340	NM_006060.4	ENST00000331340	NM_006060.4	6.0	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG, fusion	Yes		1.0
IRF4	3662	ENST00000380956	NM_002460.3	ENST00000380956	NM_002460.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	No		1.0
JUN	3725	ENST00000371222	NM_002228.3	ENST00000371222	NM_002228.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
KDM5A	5927	ENST00000399788	NM_001042603.1	ENST00000399788	NM_001042603.1	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
KDR	3791	ENST00000263923	NM_002253.2	ENST00000263923	NM_002253.2	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
KEAP1	9817	ENST00000171111	NM_203500.1	ENST00000171111	NM_203500.1	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	No		1.0
KMT2A	4297	ENST00000534358	NM_001197104.1	ENST00000534358	NM_001197104.1	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
KMT2C	58508	ENST00000262189	NM_170606.2	ENST00000262189	NM_170606.2	6.0	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	1.0	Yes	TSG	Yes		1.0
MAP2K2	5605	ENST00000262948	NM_030662.3	ENST00000262948	NM_030662.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
MAP2K4	6416	ENST00000353533	NM_003010.3	ENST00000353533	NM_003010.3	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, TSG	No		1.0
MAPK1	5594	ENST00000215832	NM_002745.4	ENST00000215832	NM_002745.4	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
MDM2	4193	ENST00000462284	NM_002392.5	ENST00000258149	NM_002392.5	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
MDM4	4194	ENST00000367182	NM_002393.4	ENST00000367182	NM_002393.4	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
MITF	4286	ENST00000394351	NM_000248.3	ENST00000394351	NM_000248.3	6.0	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
MTOR	2475	ENST00000361445	NM_004958.3	ENST00000361445	NM_004958.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes	mTOR deregulation has been observed in many cancer types. As a part of the PI3K/Akt pathway, there is a broad interest in mTOR biology across cancer types. mTOR inhibition has been investigated for nearly a decade. Everolimus, temsirolimus and zotarolimus are three of the more commonly used mTOR inhibitors used in clinical treatment today, with modest success.	1.0
MUTYH	4595	ENST00000372115	NM_001048171.1	ENST00000372115	NM_001048171.1	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	No		1.0
MYC	4609	ENST00000377970	NM_002467.4	ENST00000621592	NM_002467.4	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
MYCL	4610	ENST00000397332	NM_001033082.2	ENST00000397332	NM_001033082.2	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
MYCN	4613	ENST00000281043	NM_005378.4	ENST00000281043	NM_005378.4	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
NKX2-1	7080	ENST00000354822	NM_001079668.2	ENST00000354822	NM_001079668.2	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, TSG	No		1.0
NSD2	7468	ENST00000382891	NM_001042424.2	ENST00000382891	NM_001042424.2	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
NSD3	54904	ENST00000317025	NM_023034.1	ENST00000317025	NM_023034.1	6.0	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
NTRK1	4914	ENST00000524377	NM_002529.3	ENST00000524377	NM_002529.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	Yes		1.0
NTRK3	4916	ENST00000360948	NM_001012338.2	ENST00000360948	NM_001012338.2	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
PALB2	79728	ENST00000261584	NM_024675.3	ENST00000261584	NM_024675.3	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	Yes		1.0
PDCD1LG2	80380	ENST00000397747	NM_025239.3	ENST00000397747	NM_025239.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
PDGFRB	5159	ENST00000261799	NM_002609.3	ENST00000261799	NM_002609.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
PHF6	84295	ENST00000332070	NM_001015877.1	ENST00000332070	NM_001015877.1	6.0	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	1.0	Yes	TSG	No		1.0
PIM1	5292	ENST00000373509	NM_002648.3	ENST00000373509	NM_002648.3	6.0	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
PRKAR1A	5573	ENST00000358598	NM_212471.2	ENST00000358598	NM_212471.2	6.0	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	Yes		1.0
RAD21	5885	ENST00000297338	NM_006265.2	ENST00000297338	NM_006265.2	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, TSG	No		1.0
RAF1	5894	ENST00000251849	NM_002880.3	ENST00000251849	NM_002880.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
RARA	5914	ENST00000254066	NM_000964.3	ENST00000254066	NM_000964.3	6.0	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
ROS1	6098	ENST00000368508	NM_002944.2	ENST00000368508	NM_002944.2	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes	ROS1 is a receptor tyrosine kinase that is frequently involved in genetic rearrangement in a variety of human cancers (e.g. NSCLC, gastric cancer, ovarian cancer, cholangiocarcinoma, colorectal cancer, angiosarcoma...). The resulting fusion protein harbors the constitutively active ROS1 kinase domain and drives cellular proliferation (Davies et. al.). In NSCLC about 1% harbor a ROS1 rearrangement. These patients are predominantely female and have a lower T-stage (Warth et. al.). Treatment with crizotinib leads to a reported objective response rate of appr. 70% and a median duration of response of 18 months (Shaw et. al.). Resistance mechanisms to crizotinib have been described and involve mutations in the kinase domain. More selective inhibitors of ROS1 might overcome this resistance (Davare et. al.).	1.0
RUNX1	861	ENST00000300305	NM_001754.4	ENST00000300305	NM_001754.4	6.0	Yes	No	Yes	Yes	Yes	No	Yes	Yes	Yes	1.0	Yes	oncogene, TSG, fusion	Yes	RUNX1 is a transcription factor that forms a complex with the cofactor CBFB. This complex provides stability to the RUNX1 protein which is involved in the generation of hematopoietic stem cells and for their differentiation into myeloid and lymphoid lines.  Loss of RUNX1 function has been shown to impair differentiation between myeloid and lymphoid lines often resulting in the development of leukemia.	1.0
SDHA	6389	ENST00000264932	NM_004168.2	ENST00000264932	NM_004168.2	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	Yes		1.0
SDHB	6390	ENST00000375499	NM_003000.2	ENST00000375499	NM_003000.2	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	Yes		1.0
SDHC	6391	ENST00000367975	NM_003001.3	ENST00000367975	NM_003001.3	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	No		1.0
SDHD	6392	ENST00000375549	NM_003002.3	ENST00000375549	NM_003002.3	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	No		1.0
SOX2	6657	ENST00000325404	NM_003106.3	ENST00000325404	NM_003106.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	No		1.0
SPEN	23013	ENST00000375759	NM_015001.2	ENST00000375759	NM_015001.2	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	No		1.0
SRC	6714	ENST00000358208	NM_198291.2	ENST00000358208	NM_198291.2	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	No		1.0
SRSF2	6427	ENST00000359995	NM_003016.4	ENST00000359995	NM_003016.4	6.0	Yes	No	No	Yes	Yes	No	Yes	Yes	Yes	1.0	Yes	oncogene	Yes		1.0
STAT3	6774	ENST00000264657	NM_139276.2	ENST00000264657	NM_139276.2	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
SUFU	51684	ENST00000369902	NM_016169.3	ENST00000369902	NM_016169.3	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	Yes		1.0
SYK	6850	ENST00000375746	NM_003177.5	ENST00000375746	NM_003177.5	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
TENT5C	54855	ENST00000369448	NM_017709.3	ENST00000369448	NM_017709.3	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	No		1.0
TGFBR2	7048	ENST00000295754	NM_003242.5	ENST00000295754	NM_003242.5	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	No		1.0
TMPRSS2	7113	ENST00000398585	NM_001135099.1	ENST00000398585	NM_001135099.1	6.0	Yes	No	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	fusion	Yes		1.0
TNFRSF14	8764	ENST00000355716	NM_003820.2	ENST00000355716	NM_003820.2	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	No		1.0
TSC2	7249	ENST00000219476	NM_000548.3	ENST00000219476	NM_000548.3	6.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	Yes		1.0
TSHR	7253	ENST00000298171	NM_000369.2	ENST00000541158	NM_000369.2	6.0	Yes	Yes	No	Yes	Yes	No	Yes	Yes	Yes	1.0	Yes	oncogene	No		1.0
XPO1	7514	ENST00000401558	NM_003400.3	ENST00000401558	NM_003400.3	6.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	No		1.0
AKT3	10000	ENST00000263826	NM_005465.4	ENST00000263826	NM_005465.4	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	2.0	Yes	oncogene	Yes		1.0
ARAF	369	ENST00000377045	NM_001654.4	ENST00000377045	NM_001654.4	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No	2.0	Yes	oncogene	Yes	ARAF has recently become increasingly considered for its oncogenic potential. Its potential as a target for informing clinical action was demonstrated by a single case of advanced lung adenocarcinoma harboring an S214C mutation that, when treated with sorafenib, acheived near-complete clinical remission. This finding has brought new focus on ARAF as a marker that should be assayed for in cancer treatment.	1.0
ARID1B	57492	ENST00000346085	NM_020732.3	ENST00000647938	NM_020732.3	5.0	Yes	No	Yes	Yes	Yes	No	No	Yes	Yes	1.0	Yes	TSG	No		1.0
AURKA	6790	ENST00000312783	NM_003600.2	ENST00000312783	NM_003600.2	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		Yes		2.0
AURKB	9212	ENST00000585124	NM_004217.3	ENST00000585124	NM_004217.3	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		No		2.0
AXL	558	ENST00000301178	NM_021913.4	ENST00000301178	NM_021913.4	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		Yes		2.0
BCL10	8915	ENST00000370580	NM_003921.4	ENST00000648566	NM_003921.4	5.0	Yes	No	Yes	Yes	Yes	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		1.0
BCORL1	63035	ENST00000218147		ENST00000218147		5.0	Yes	No	Yes	No	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, TSG	No		1.0
BCR	613	ENST00000305877	NM_004327.3	ENST00000305877	NM_004327.3	5.0	Yes	Yes	No	No	Yes	Yes	Yes	No	Yes	1.0	Yes	fusion	No		1.0
BIRC3	330	ENST00000263464	NM_182962.2	ENST00000263464	NM_182962.2	5.0	Yes	No	No	Yes	Yes	No	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	Yes		1.0
BLM	641	ENST00000355112	NM_000057.2	ENST00000355112	NM_000057.2	5.0	Yes	No	Yes	Yes	Yes	No	Yes	No	Yes	1.0	Yes	TSG	No		1.0
BTG1	694	ENST00000256015	NM_001731.2	ENST00000256015	NM_001731.2	5.0	Yes	No	Yes	No	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG, fusion	No		1.0
CDK8	1024	ENST00000381527	NM_001260.1	ENST00000381527	NM_001260.1	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		No		2.0
CDKN2B	1030	ENST00000276925	NM_004936.3	ENST00000276925	NM_004936.3	5.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No		No		Yes		2.0
CHEK1	1111	ENST00000428830	NM_001274.5	ENST00000428830	NM_001274.5	5.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No		No		Yes		2.0
CRKL	1399	ENST00000354336	NM_005207.3	ENST00000354336	NM_005207.3	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		Yes		2.0
CYLD	1540	ENST00000398568	NM_001042355.1	ENST00000398568	NM_001042355.1	5.0	Yes	No	Yes	Yes	Yes	No	No	Yes	Yes	1.0	Yes	TSG	No		1.0
DOT1L	84444	ENST00000398665	NM_032482.2	ENST00000398665	NM_032482.2	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		No		2.0
EED	8726	ENST00000263360	NM_003797.3	ENST00000263360	NM_003797.3	5.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	2.0	Yes	TSG	No		1.0
EIF4A2	1974	ENST00000323963	NM_001967.3	ENST00000323963	NM_001967.3	5.0	Yes	Yes	No	Yes	Yes	No	Yes	No	Yes	1.0	Yes	fusion	No		1.0
EPHA3	2042	ENST00000336596	NM_005233.5	ENST00000336596	NM_005233.5	5.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	2.0	Yes		No		1.0
EPHB1	2047	ENST00000398015	NM_004441.4	ENST00000398015	NM_004441.4	5.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No		No		No		2.0
ERCC4	2072	ENST00000311895	NM_005236.2	ENST00000311895	NM_005236.2	5.0	Yes	No	Yes	Yes	Yes	Yes	No	No	Yes	1.0	Yes	TSG	No		1.0
ETV1	2115	ENST00000405192	NM_001163147.1	ENST00000405192	NM_001163147.1	5.0	Yes	Yes	No	Yes	Yes	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
FAS	355	ENST00000355740	NM_000043.4	ENST00000652046	NM_000043.4	5.0	Yes	No	Yes	No	Yes	Yes	Yes	No	Yes	1.0	Yes	TSG	No		1.0
FGF19	9965	ENST00000294312	NM_005117.2	ENST00000294312	NM_005117.2	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		Yes		2.0
FGF3	2248	ENST00000334134	NM_005247.2	ENST00000334134	NM_005247.2	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		Yes	FGF3 is a member of the basic fibroblast growth factor (FGF) gene family and was first identified  based on it's similarity to the mouse proto-oncogene int-2. Amplifications of this gene and the surrounding region (11q13) have been observed in various cancers including breast cancer, esophogeal cancer, melanoma, bladder cancer and hepatocellular carcinoma (HCC). Lower tumor grade and stage have been associated with FGF3 amplifications in HCC; however, this event is fairly rare in this tumor type.	2.0
FGF4	2249	ENST00000168712	NM_002007.2	ENST00000168712	NM_002007.2	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		No		2.0
FH	2271	ENST00000366560	NM_000143.3	ENST00000366560	NM_000143.3	5.0	Yes	No	Yes	Yes	Yes	Yes	No	No	Yes	1.0	Yes	TSG	No		1.0
FLT1	2321	ENST00000282397	NM_002019.4	ENST00000282397	NM_002019.4	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		No		2.0
FLT4	2324	ENST00000261937	NM_182925.4	ENST00000261937	NM_182925.4	5.0	Yes	Yes	No	Yes	Yes	No	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
FOXO1	2308	ENST00000379561	NM_002015.3	ENST00000379561	NM_002015.3	5.0	Yes	No	Yes	Yes	Yes	No	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	Yes		1.0
FOXP1	27086	ENST00000318789	NM_001244814.1	ENST00000318789	NM_001244814.1	5.0	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
GRIN2A	2903	ENST00000330684	NM_001134407.1	ENST00000330684	NM_001134407.1	5.0	Yes	No	Yes	Yes	Yes	No	Yes	No	Yes	1.0	Yes	TSG	No		1.0
GSK3B	2932	ENST00000316626	NM_002093.3	ENST00000316626	NM_002093.3	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		No		2.0
HGF	3082	ENST00000222390	NM_000601.4	ENST00000222390	NM_000601.4	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		Yes		2.0
ID3	3399	ENST00000374561	NM_002167.4	ENST00000374561	NM_002167.4	5.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No	2.0	Yes	TSG	No		1.0
IGF1R	3480	ENST00000268035	NM_000875.3	ENST00000650285	NM_000875.3	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		Yes		2.0
IKBKE	9641	ENST00000367120	NM_014002.3	ENST00000581977	NM_014002.3	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		No		2.0
IL7R	3575	ENST00000303115	NM_002185.3	ENST00000303115	NM_002185.3	5.0	Yes	Yes	No	Yes	Yes	No	Yes	No	Yes	1.0	Yes	oncogene	Yes		1.0
INPP4B	8821	ENST00000262992	NM_001101669.1	ENST00000262992	NM_001101669.1	5.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No		No		No		2.0
IRS2	8660	ENST00000375856	NM_003749.2	ENST00000375856	NM_003749.2	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		Yes		2.0
KLF4	9314	ENST00000374672	NM_004235.4	ENST00000374672	NM_004235.4	5.0	Yes	Yes	Yes	Yes	Yes	No	No	Yes	Yes	1.0	Yes	oncogene, TSG	Yes		1.0
LMO1	4004	ENST00000335790	NM_002315.2	ENST00000335790	NM_002315.2	5.0	Yes	Yes	No	Yes	Yes	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
MALT1	10892	ENST00000348428	NM_006785.3	ENST00000649217	NM_006785.3	5.0	Yes	No	No	Yes	Yes	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
MAP3K13	9175	ENST00000265026	NM_004721.4	ENST00000265026	NM_004721.4	5.0	Yes	Yes	No	Yes	Yes	Yes	No	No	Yes	1.0	Yes	oncogene, TSG	No		1.0
MCL1	4170	ENST00000369026	NM_021960.4	ENST00000369026	NM_021960.4	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		No		2.0
MEF2B	100271849	ENST00000162023	NM_001145785.1	ENST00000424583	NM_001145785.1	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		No		2.0
MRE11	4361	ENST00000323929	NM_005591.3	ENST00000323929	NM_005591.3	5.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No		No		Yes		2.0
MSH3	4437	ENST00000265081	NM_002439.4	ENST00000265081	NM_002439.4	5.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No		No		Yes		2.0
MSI2	124540	ENST00000284073	NM_138962.2	ENST00000284073	NM_138962.2	5.0	Yes	Yes	No	Yes	Yes	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
NBN	4683	ENST00000265433	NM_002485.4	ENST00000265433	NM_002485.4	5.0	Yes	No	Yes	Yes	Yes	Yes	No	No	Yes	1.0	Yes	TSG	Yes		1.0
NCOR1	9611	ENST00000268712	NM_006311.3	ENST00000268712	NM_006311.3	5.0	Yes	No	Yes	Yes	Yes	No	No	Yes	Yes	1.0	Yes	TSG	No		1.0
NFKBIA	4792	ENST00000216797	NM_020529.2	ENST00000216797	NM_020529.2	5.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No		No		No		2.0
NSD1	64324	ENST00000439151	NM_022455.4	ENST00000439151	NM_022455.4	5.0	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes	1.0	Yes	fusion	No		1.0
NT5C2	22978	ENST00000343289	NM_001134373.2	ENST00000343289	NM_001134373.2	5.0	Yes	Yes	No	No	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene	Yes	This gene, when mutated to be over-active, has been linked to chemotherapy resistance in relapsed T-cell Acute Lymphoblastic Leukemia.	1.0
NTRK2	4915	ENST00000277120	NM_006180.3	ENST00000277120	NM_006180.3	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		Yes		2.0
P2RY8	286530	ENST00000381297	NM_178129.4	ENST00000381297	NM_178129.4	5.0	Yes	No	Yes	No	Yes	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
PDCD1	5133	ENST00000334409	NM_005018.2	ENST00000334409	NM_005018.2	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		No		2.0
PIK3CB	5291	ENST00000289153	NM_006219.2	ENST00000289153	NM_006219.2	5.0	Yes	Yes	No	Yes	Yes	Yes	No	No	Yes	1.0	Yes	oncogene	Yes		1.0
PMS2	5395	ENST00000265849	NM_000535.5	ENST00000265849	NM_000535.5	5.0	Yes	No	Yes	Yes	Yes	Yes	No	No	Yes	1.0	Yes	TSG	Yes		1.0
POLD1	5424	ENST00000440232	NM_002691.3	ENST00000440232	NM_002691.3	5.0	Yes	No	Yes	Yes	Yes	Yes	No	No	Yes	1.0	Yes	TSG	Yes		1.0
POLE	5426	ENST00000320574	NM_006231.2	ENST00000320574	NM_006231.2	5.0	Yes	No	Yes	Yes	Yes	Yes	No	No	Yes	1.0	Yes	TSG	Yes		1.0
POT1	25913	ENST00000357628	NM_015450.2	ENST00000357628	NM_015450.2	5.0	Yes	No	Yes	Yes	Yes	No	Yes	No	Yes	1.0	Yes	TSG	Yes		1.0
PPARG	5468	ENST00000287820	NM_015869.4	ENST00000287820	NM_015869.4	5.0	Yes	Yes	No	Yes	Yes	Yes	No	No	Yes	1.0	Yes	TSG, fusion	No		1.0
RAC1	5879	ENST00000356142	NM_018890.3	ENST00000356142	NM_018890.3	5.0	Yes	Yes	No	Yes	Yes	Yes	No	No	Yes	1.0	Yes	oncogene	Yes	The RAC1 P29S mutation is the third most common protein-coding hotspot mutation in melanomas, ocurring in 4-9%. A preclinical study has shown that this mutation confers resistance to BRAF inhibition in-vitro.	1.0
RAD51	5888	ENST00000267868	NM_002875.4	ENST00000267868	NM_002875.4	5.0	Yes	No	Yes	Yes	Yes	Yes	Yes	No	No		No		No		2.0
RAD51B	5890	ENST00000487270	NM_133509.3	ENST00000487270	NM_133509.3	5.0	Yes	No	Yes	Yes	Yes	Yes	No	No	Yes	1.0	Yes	TSG, fusion	No		1.0
RBM10	8241	ENST00000329236	NM_001204468.1	ENST00000628161	NM_001204468.1	5.0	Yes	No	Yes	Yes	Yes	Yes	No	No	Yes	1.0	Yes	TSG	No		1.0
REL	5966	ENST00000295025	NM_002908.2	ENST00000295025	NM_002908.2	5.0	Yes	Yes	No	Yes	Yes	Yes	No	No	Yes	1.0	Yes	oncogene	Yes		1.0
RHOA	387	ENST00000418115	NM_001664.2	ENST00000418115	NM_001664.2	5.0	Yes	Yes	No	Yes	Yes	No	Yes	No	Yes	1.0	Yes	oncogene, TSG	Yes		1.0
RICTOR	253260	ENST00000357387	NM_152756.3	ENST00000357387	NM_152756.3	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		Yes		2.0
RPTOR	57521	ENST00000306801	NM_020761.2	ENST00000306801	NM_020761.2	5.0	Yes	Yes	No	Yes	Yes	Yes	Yes	No	No		No		No		2.0
SETBP1	26040	ENST00000282030	NM_015559.2	ENST00000649279	NM_015559.2	5.0	Yes	Yes	No	No	Yes	No	Yes	Yes	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
SOX9	6662	ENST00000245479	NM_000346.3	ENST00000245479	NM_000346.3	5.0	Yes	Yes	Yes	Yes	Yes	Yes	No	Yes	No		No		No		2.0
STAT5B	6777	ENST00000293328	NM_012448.3	ENST00000293328	NM_012448.3	5.0	Yes	Yes	No	Yes	Yes	No	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	Yes		1.0
SUZ12	23512	ENST00000322652	NM_015355.2	ENST00000322652	NM_015355.2	5.0	Yes	No	Yes	Yes	Yes	No	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	No		1.0
TBX3	6926	ENST00000257566	NM_016569.3	ENST00000257566	NM_016569.3	5.0	Yes	No	Yes	Yes	Yes	Yes	No	No	Yes	1.0	Yes	oncogene, TSG	No		1.0
TCF3	6929	ENST00000344749	NM_001136139.2	ENST00000588136	NM_001136139.2	5.0	Yes	No	Yes	Yes	Yes	No	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	No		1.0
TERT	7015	ENST00000310581	NM_198253.2	ENST00000310581	NM_198253.2	5.0	Yes	Yes	No	Yes	Yes	Yes	No	No	Yes	1.0	Yes	oncogene, TSG	Yes		1.0
TET1	80312	ENST00000373644	NM_030625.2	ENST00000373644	NM_030625.2	5.0	Yes	No	Yes	Yes	Yes	No	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	No		1.0
TOP1	7150	ENST00000361337	NM_003286.2	ENST00000361337	NM_003286.2	5.0	Yes	No	Yes	Yes	Yes	No	Yes	No	Yes	1.0	Yes	fusion	Yes		1.0
TP63	8626	ENST00000264731	NM_003722.4	ENST00000264731	NM_003722.4	5.0	Yes	Yes	Yes	Yes	Yes	No	Yes	No	Yes	1.0	Yes	oncogene, TSG	No		1.0
TRAF7	84231	ENST00000326181	NM_032271.2	ENST00000326181	NM_032271.2	5.0	Yes	No	No	Yes	Yes	No	No	Yes	Yes	1.0	Yes	TSG	No		1.0
ZRSR2	8233	ENST00000307771	NM_005089.3	ENST00000307771	NM_005089.3	5.0	Yes	No	No	Yes	Yes	No	Yes	No	Yes	1.0	Yes	TSG	Yes		1.0
ACVR1	90	ENST00000263640	NM_001111067.2	ENST00000263640	NM_001111067.2	4.0	Yes	Yes	No	Yes	Yes	No	No	No	Yes	1.0	Yes	oncogene	Yes		1.0
ALOX12B	242	ENST00000319144	NM_001139.2	ENST00000647874	NM_001139.2	4.0	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No		No		No		2.0
AXIN2	8313	ENST00000307078	NM_004655.3	ENST00000307078	NM_004655.3	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	TSG	No		1.0
BCL11B	64919	ENST00000357195	NM_138576.3	ENST00000357195	NM_138576.3	4.0	Yes	No	Yes	No	Yes	No	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	No		1.0
BCL2L1	598	ENST00000307677	NM_138578.1	ENST00000307677	NM_138578.1	4.0	Yes	No	No	Yes	Yes	Yes	No	No	No		No		No		2.0
BMPR1A	657	ENST00000372037	NM_004329.2	ENST00000372037	NM_004329.2	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	oncogene, TSG	No		1.0
CDKN1A	1026	ENST00000244741	NM_078467.2	ENST00000244741	NM_078467.2	4.0	Yes	No	Yes	Yes	Yes	Yes	No	No	No	2.0	Yes	oncogene, TSG	Yes		1.0
CIITA	4261	ENST00000324288	NM_001286402	ENST00000324288	NM_001286402	4.0	Yes	No	Yes	No	Yes	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		1.0
CUL3	8452	ENST00000264414	NM_003590.4	ENST00000264414	NM_003590.4	4.0	Yes	No	Yes	Yes	Yes	Yes	No	No	No	2.0	Yes	TSG	No		1.0
CUX1	1523	ENST00000292535	NM_181552.3	ENST00000292535	NM_181552.3	4.0	Yes	No	Yes	No	Yes	No	Yes	No	Yes	1.0	Yes	oncogene, TSG	No		1.0
DDX3X	1654	ENST00000399959	NM_001356.4	ENST00000478993	NM_001356.4	4.0	Yes	No	Yes	No	Yes	No	Yes	No	Yes	1.0	Yes	TSG	No		1.0
DICER1	23405	ENST00000393063	NM_177438.2	ENST00000393063	NM_177438.2	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	TSG	Yes		1.0
DIS3	22894	ENST00000377767	NM_014953.3	ENST00000377767	NM_014953.3	4.0	Yes	No	Yes	Yes	Yes	Yes	No	No	No		No		No		2.0
DNAJB1	3337	ENST00000254322	NM_006145.1	ENST00000254322	NM_006145.1	4.0	Yes	No	No	Yes	Yes	No	No	No	Yes	1.0	Yes	fusion	No		1.0
DNMT1	1786	ENST00000340748	NM_001379.2	ENST00000340748	NM_001379.2	4.0	Yes	Yes	No	Yes	Yes	No	No	Yes	No		No		Yes		2.0
DROSHA	29102	ENST00000344624	NM_013235.4	ENST00000344624	NM_013235.4	4.0	Yes	No	No	Yes	Yes	No	No	No	Yes	1.0	Yes	TSG	Yes		1.0
EPAS1	2034	ENST00000263734	NM_001430.4	ENST00000263734	NM_001430.4	4.0	Yes	No	No	Yes	Yes	No	No	No	Yes	1.0	Yes	oncogene, TSG	Yes		1.0
EPHA5	2044	ENST00000273854	NM_004439.5	ENST00000273854	NM_004439.5	4.0	Yes	No	No	Yes	Yes	No	Yes	No	No		No		No		2.0
EPHA7	2045	ENST00000369303	NM_004440.3	ENST00000369303	NM_004440.3	4.0	Yes	Yes	Yes	Yes	Yes	No	Yes	No	No	2.0	Yes		No		1.0
ERCC2	2068	ENST00000391945	NM_000400.3	ENST00000391945	NM_000400.3	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	TSG	Yes	ERCC2 functions as a DNA repair gene involved in separating the double helix via 5’-3’ helicase activity. It forms a part of the transcription factor II Human (TFIIH) complex and is ATP-dependent. The TFIIH complex is known to be involved in the nucleotide excision repair pathway (NER) which can repair DNA damage caused by chemotherapeutic treatment and basal transcription. ERCC2 variants have been observed in a variety of cancers. A number of studies have suggested ERCC2 variants can act as biomarkers to predict response to neoadjuvant treatment, and cancer prognosis. Additionally the Lys751Gln polymorphism has been observed to increase risk in a number of cancer types; however, results have been conflicting.	1.0
ERCC3	2071	ENST00000285398	NM_000122.1	ENST00000285398	NM_000122.1	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	TSG	No		1.0
ERCC5	2073	ENST00000355739	NM_000123.3	ENST00000652225	NM_000123.3	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes		No		Yes		2.0
ERRFI1	54206	ENST00000377482	NM_018948.3	ENST00000377482	NM_018948.3	4.0	Yes	No	Yes	Yes	Yes	Yes	No	No	No		No		Yes		2.0
ETV4	2118	ENST00000319349	NM_001079675.2	ENST00000319349	NM_001079675.2	4.0	Yes	Yes	No	No	No	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
ETV5	2119	ENST00000306376	NM_004454.2	ENST00000306376	NM_004454.2	4.0	Yes	Yes	No	No	No	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
EWSR1	2130	ENST00000397938	NM_005243.3	ENST00000397938	NM_005243.3	4.0	Yes	Yes	No	No	No	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes	Fusions between EWSR1 and multiple 3` partners are regularly identified in soft tissue sarcomas and can aid in differential diagnosis. The fusion product usually contains the N-terminal transcription-activating domain of EWSR1 and the C-terminal DNA-binding domain of the fusion partner, generating a novel transcription factor.	1.0
FANCD2	2177	ENST00000383807	NM_001018115.1	ENST00000383807	NM_001018115.1	4.0	Yes	No	Yes	No	Yes	No	Yes	No	Yes	1.0	Yes	TSG	No		1.0
FAT1	2195	ENST00000441802	NM_005245.3	ENST00000441802	NM_005245.3	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	TSG	No		1.0
FBXO11	80204	ENST00000403359	NM_001190274.1	ENST00000403359	NM_001190274.1	4.0	Yes	No	Yes	No	Yes	No	Yes	No	Yes	1.0	Yes	TSG	No		1.0
FOXA1	3169	ENST00000250448	NM_004496.3	ENST00000250448	NM_004496.3	4.0	Yes	Yes	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	oncogene	No		1.0
GLI1	2735	ENST00000228682	NM_005269.2	ENST00000228682	NM_005269.2	4.0	Yes	Yes	No	Yes	Yes	No	Yes	No	No	2.0	Yes	oncogene, fusion	Yes		1.0
GNA13	10672	ENST00000439174	NM_006572.5	ENST00000439174	NM_006572.5	4.0	Yes	Yes	No	No	Yes	Yes	Yes	No	No		No		No		2.0
H1-2	3006	ENST00000343677	NM_005319.3	ENST00000343677	NM_005319.3	4.0	Yes	No	No	Yes	Yes	No	Yes	No	No		No		No		2.0
H3-3B	3021	ENST00000254810	NM_005324.3	ENST00000254810	NM_005324.3	4.0	Yes	No	No	Yes	Yes	No	No	No	Yes		No		Yes		2.0
HDAC1	3065	ENST00000373548	NM_004964.2	ENST00000373548	NM_004964.2	4.0	Yes	Yes	No	No	Yes	Yes	Yes	No	No		No		No		2.0
HLA-A	3105	ENST00000376809	NM_001242758.1	ENST00000376809	NM_001242758.1	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	fusion	No		1.0
INHBA	3624	ENST00000242208	NM_002192.2	ENST00000242208	NM_002192.2	4.0	Yes	Yes	Yes	Yes	Yes	No	Yes	No	No		No		No		2.0
LATS1	9113	ENST00000253339	NM_004690.3	ENST00000253339	NM_004690.3	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	TSG	No		1.0
LATS2	26524	ENST00000382592	NM_014572.2	ENST00000382592	NM_014572.2	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	TSG	No		1.0
LYN	4067	ENST00000519728	NM_002350.3	ENST00000519728	NM_002350.3	4.0	Yes	Yes	No	Yes	Yes	Yes	No	No	No		No		Yes		2.0
MAF	4094	ENST00000393350	NM_001031804.2	ENST00000393350	NM_001031804.2	4.0	Yes	No	No	No	No	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
MAP3K14	9020	ENST00000344686	NM_003954.3	ENST00000344686	NM_003954.3	4.0	Yes	Yes	No	Yes	Yes	No	Yes	No	No		No		No		2.0
MAX	4149	ENST00000358664	NM_002382.4	ENST00000358664	NM_002382.4	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	TSG	No		1.0
MLLT1	4298	ENST00000252674	NM_005934.3	ENST00000252674	NM_005934.3	4.0	Yes	No	No	Yes	No	No	Yes	No	Yes	1.0	Yes	fusion	No		1.0
MST1R	4486	ENST00000296474	NM_002447.2	ENST00000296474	NM_002447.2	4.0	Yes	Yes	No	Yes	Yes	Yes	No	No	No		No		No		2.0
MYOD1	4654	ENST00000250003	NM_002478.4	ENST00000250003	NM_002478.4	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	oncogene	Yes		1.0
NCOR2	9612	ENST00000405201	NM_006312.6	ENST00000405201	NM_006312.6	4.0	Yes	No	No	No	Yes	No	Yes	No	Yes	1.0	Yes	TSG	No		1.0
NOTCH3	4854	ENST00000263388	NM_000435.2	ENST00000263388	NM_000435.2	4.0	Yes	Yes	Yes	Yes	Yes	Yes	No	No	No		No		Yes		2.0
NUP93	9688	ENST00000308159	NM_014669.4	ENST00000308159	NM_014669.4	4.0	Yes	No	No	Yes	Yes	No	Yes	No	No		No		No		2.0
PARP1	142	ENST00000366794	NM_001618.3	ENST00000366794	NM_001618.3	4.0	Yes	No	Yes	Yes	Yes	Yes	No	No	No		No		Yes		2.0
PHOX2B	8929	ENST00000226382	NM_003924.3	ENST00000226382	NM_003924.3	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	TSG	No		1.0
PIK3C2G	5288	ENST00000266497	NM_004570.4	ENST00000433979	NM_004570.4	4.0	Yes	No	No	Yes	Yes	Yes	No	No	No		No		No		2.0
PIK3CG	5294	ENST00000359195	NM_002649.2	ENST00000359195	NM_002649.2	4.0	Yes	Yes	No	Yes	Yes	No	Yes	No	No		No		No		2.0
PIK3R2	5296	ENST00000222254	NM_005027.3	ENST00000222254	NM_005027.3	4.0	Yes	No	Yes	Yes	Yes	No	Yes	No	No		No		Yes		2.0
PLCG2	5336	ENST00000359376	NM_002661.3	ENST00000564138	NM_002661.3	4.0	Yes	Yes	No	Yes	Yes	No	Yes	No	No		No		Yes		2.0
PPM1D	8493	ENST00000305921	NM_003620.3	ENST00000305921	NM_003620.3	4.0	Yes	Yes	No	Yes	Yes	No	No	No	Yes	1.0	Yes	oncogene	No		1.0
PPP6C	5537	ENST00000373547	NM_002721.4	ENST00000373547	NM_002721.4	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	TSG	No		1.0
PREX2	80243	ENST00000288368	NM_024870.2	ENST00000288368	NM_024870.2	4.0	Yes	No	No	Yes	Yes	No	No	No	Yes	1.0	Yes	oncogene	Yes		1.0
PRKCI	5584	ENST00000295797	NM_002740.5	ENST00000295797	NM_002740.5	4.0	Yes	Yes	No	Yes	Yes	Yes	No	No	No		No		No		2.0
PRKN	5071	ENST00000366898	NM_004562.2	ENST00000366898	NM_004562.2	4.0	Yes	No	Yes	Yes	Yes	Yes	No	No	No		No		Yes		2.0
PTPRT	11122	ENST00000373198	NM_133170.3	ENST00000373198	NM_133170.3	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	TSG	Yes		1.0
RAD50	10111	ENST00000265335	NM_005732.3	ENST00000378823	NM_005732.3	4.0	Yes	No	Yes	Yes	Yes	No	Yes	No	No		No		Yes		2.0
RAD51C	5889	ENST00000337432	NM_058216.2	ENST00000337432	NM_058216.2	4.0	Yes	No	Yes	Yes	Yes	Yes	No	No	No		No		No		2.0
RAD51D	5892	ENST00000345365	NM_002878.3	ENST00000345365	NM_002878.3	4.0	Yes	No	Yes	Yes	Yes	Yes	No	No	No		No		Yes		2.0
RAD52	5893	ENST00000358495	NM_134424.2	ENST00000358495	NM_134424.2	4.0	Yes	No	No	Yes	Yes	Yes	No	No	No		No		No		2.0
RAD54L	8438	ENST00000371975	NM_001142548.1	ENST00000371975	NM_001142548.1	4.0	Yes	No	No	Yes	Yes	Yes	No	No	No		No		No		2.0
RECQL4	9401	ENST00000428558	NM_004260.3	ENST00000617875	NM_004260.3	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	oncogene, TSG	No		1.0
RUNX1T1	862	ENST00000265814	NM_001198626.1	ENST00000265814	NM_001198626.1	4.0	Yes	Yes	No	No	Yes	No	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	No		1.0
SDHAF2	54949	ENST00000301761	NM_017841.2	ENST00000301761	NM_017841.2	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	TSG	No		1.0
SGK1	6446	ENST00000237305	NM_005627.3	ENST00000237305	NM_005627.3	4.0	Yes	Yes	No	No	Yes	Yes	Yes	No	No	2.0	Yes	oncogene	Yes		1.0
SH2B3	10019	ENST00000341259	NM_005475.2	ENST00000341259	NM_005475.2	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	TSG	Yes		1.0
SMAD3	4088	ENST00000327367	NM_005902.3	ENST00000327367	NM_005902.3	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	TSG	No		1.0
SMARCD1	6602	ENST00000394963	NM_003076.4	ENST00000394963	NM_003076.4	4.0	Yes	No	No	Yes	Yes	No	No	No	Yes	1.0	Yes	TSG	No		1.0
STAT5A	6776	ENST00000345506	NM_003152.3	ENST00000345506	NM_003152.3	4.0	Yes	Yes	No	Yes	Yes	No	Yes	No	No		No		No		2.0
STAT6	6778	ENST00000300134	NM_001178078.1	ENST00000300134	NM_001178078.1	4.0	Yes	Yes	No	No	Yes	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
TBL1XR1	79718	ENST00000430069	NM_024665.4	ENST00000430069	NM_024665.4	4.0	Yes	No	Yes	No	Yes	No	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	No		1.0
TCF7L2	6934	ENST00000543371	NM_001146274.1	ENST00000627217	NM_001146274.1	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
TEK	7010	ENST00000380036	NM_000459.3	ENST00000380036	NM_000459.3	4.0	Yes	No	No	Yes	Yes	Yes	No	No	No		No		Yes		2.0
TMEM127	55654	ENST00000258439	NM_001193304.2	ENST00000258439	NM_001193304.2	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	TSG	No		1.0
TRAF2	7186	ENST00000247668	NM_021138.3	ENST00000247668	NM_021138.3	4.0	Yes	No	No	Yes	Yes	No	Yes	No	No		No		No		2.0
VEGFA	7422	ENST00000523873	NM_001171623.1	ENST00000523873	NM_001171623.1	4.0	Yes	Yes	No	Yes	Yes	Yes	No	No	No		No		Yes		2.0
WWTR1	25937	ENST00000360632	NM_001168280.1	ENST00000360632	NM_001168280.1	4.0	Yes	Yes	No	Yes	Yes	No	No	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
XRCC2	7516	ENST00000359321	NM_005431.1	ENST00000359321	NM_005431.1	4.0	Yes	No	Yes	Yes	Yes	Yes	No	No	No		No		No		2.0
ZFHX3	463	ENST00000268489	NM_006885.3	ENST00000268489	NM_006885.3	4.0	Yes	No	Yes	Yes	Yes	No	No	No	Yes	1.0	Yes	TSG	No		1.0
ABL2	27	ENST00000502732	NM_007314.3	ENST00000502732	NM_007314.3	3.0	Yes	Yes	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
ABRAXAS1	84142	ENST00000321945	NM_139076.2	ENST00000321945	NM_139076.2	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
AGO2	27161	ENST00000220592	NM_012154.3	ENST00000220592	NM_012154.3	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
ANKRD11	29123	ENST00000301030	NM_013275.5	ENST00000301030	NM_013275.5	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
ARID5B	84159	ENST00000279873	NM_032199.2	ENST00000279873	NM_032199.2	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
ASXL2	55252	ENST00000435504	NM_018263.4	ENST00000435504	NM_018263.4	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No	2.0	Yes	TSG	No		1.0
ATF1	466	ENST00000262053	NM_005171.4	ENST00000262053	NM_005171.4	3.0	Yes	Yes	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
BABAM1	29086	ENST00000359435	NM_001033549.1	ENST00000359435	NM_001033549.1	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
BBC3	27113	ENST00000449228	NM_001127240.2	ENST00000449228	NM_001127240.2	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
BCL2L11	10018	ENST00000393256	NM_138621.4	ENST00000393256	NM_138621.4	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		Yes		2.0
BCL9	607	ENST00000234739	NM_004326.3	ENST00000234739	NM_004326.3	3.0	Yes	Yes	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
CARM1	10498	ENST00000327064	NM_199141.1	ENST00000327064	NM_199141.1	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
CCNQ	92002	ENST00000576892	NM_152274.4	ENST00000576892	NM_152274.4	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
CD276	80381	ENST00000318443	NM_001024736.1	ENST00000318443	NM_001024736.1	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
CD58	965	ENST00000369489	NM_001779.2	ENST00000369489	NM_001779.2	3.0	Yes	No	Yes	No	Yes	No	Yes	No	No		No		No		2.0
CDC42	998	ENST00000344548	NM_001791.3	ENST00000344548	NM_001791.3	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
CENPA	1058	ENST00000335756	NM_001809.3	ENST00000335756	NM_001809.3	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
COP1	64326	ENST00000367669	NM_022457.5	ENST00000367669	NM_022457.5	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
CSDE1	7812	ENST00000438362	NM_001242891.1	ENST00000438362	NM_001242891.1	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
CTLA4	1493	ENST00000302823	NM_005214.4	ENST00000648405	NM_005214.4	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		Yes		2.0
CYSLTR2	57105	ENST00000282018	NM_020377.2	ENST00000282018	NM_020377.2	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No	2.0	Yes	oncogene	No		1.0
DCUN1D1	54165	ENST00000292782	NM_020640.2	ENST00000292782	NM_020640.2	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
DDIT3	1649	ENST00000346473	NM_001195057.1	ENST00000346473	NM_001195057.1	3.0	Yes	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
DEK	7913	ENST00000397239	NM_003472.3	ENST00000652689	NM_003472.3	3.0	Yes	Yes	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
DNMT3B	1789	ENST00000328111	NM_006892.3	ENST00000328111	NM_006892.3	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
DTX1	1840	ENST00000257600	NM_004416.2	ENST00000257600	NM_004416.2	3.0	Yes	No	Yes	No	Yes	No	Yes	No	No		No		No		2.0
DUSP22	56940	ENST00000344450	NM_020185.4	ENST00000344450	NM_020185.4	3.0	Yes	No	Yes	No	Yes	No	Yes	No	No		No		No		2.0
DUSP4	1846	ENST00000240100	NM_001394.6	ENST00000240100	NM_001394.6	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
E2F3	1871	ENST00000346618	NM_001949.4	ENST00000346618	NM_001949.4	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
EGFL7	51162	ENST00000308874	NM_201446.2	ENST00000308874	NM_201446.2	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
EIF1AX	1964	ENST00000379607	NM_001412.3	ENST00000379607	NM_001412.3	3.0	Yes	No	No	Yes	Yes	No	No	No	No	2.0	Yes		Yes		1.0
EIF4E	1977	ENST00000280892	NM_001130678.1	ENST00000280892	NM_001130678.1	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
ELF3	1999	ENST00000359651	NM_004433.4	ENST00000359651	NM_004433.4	3.0	Yes	Yes	Yes	Yes	Yes	No	No	No	No	2.0	Yes	TSG	No		1.0
ELOC	6921	ENST00000284811	NM_005648.3	ENST00000284811	NM_005648.3	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
EPCAM	4072	ENST00000263735	NM_002354.2	ENST00000263735	NM_002354.2	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		Yes		2.0
ERF	2077	ENST00000222329	NM_006494.2	ENST00000222329	NM_006494.2	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
ETNK1	55500	ENST00000266517	NM_018638.4	ENST00000671733	NM_018638.4	3.0	Yes	No	No	No	Yes	No	No	No	Yes	1.0	Yes	TSG	No		1.0
EZH1	2145	ENST00000428826	NM_001991.3	ENST00000428826	NM_001991.3	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
FANCG	2189					3.0	No	No	No	No	No	Yes	Yes	No	Yes	1.0	Yes	TSG	No		
FANCL	55120	ENST00000233741	NM_018062.3	ENST00000233741	NM_018062.3	3.0	Yes	No	Yes	No	No	Yes	Yes	No	No		No		No		2.0
FEV	54738	ENST00000295727	NM_017521.2	ENST00000295727	NM_017521.2	3.0	Yes	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
FLI1	2313	ENST00000527786	NM_002017.4	ENST00000527786	NM_002017.4	3.0	Yes	Yes	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
FYN	2534	ENST00000368678	NM_153047.3	ENST00000368678	NM_153047.3	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
GNA12	2768	ENST00000275364	NM_007353.2	ENST00000275364	NM_007353.2	3.0	Yes	Yes	No	No	Yes	No	Yes	No	No		No		No		2.0
GNB1	2782	ENST00000378609	NM_001282539.1	ENST00000378609	NM_001282539.1	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
GPS2	2874	ENST00000380728	NM_004489.4	ENST00000380728	NM_004489.4	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
GREM1	26585	ENST00000300177	NM_013372.6	ENST00000300177	NM_013372.6	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
H1-3	3007	ENST00000244534	NM_005320.2	ENST00000244534	NM_005320.2	3.0	Yes	No	Yes	No	Yes	No	Yes	No	No		No		No		2.0
H1-4	3008	ENST00000304218	NM_005321.2	ENST00000304218	NM_005321.2	3.0	Yes	Yes	No	No	Yes	No	Yes	No	No		No		No		2.0
H2AC11	8969	ENST00000358739	NM_003509.2	ENST00000358739	NM_003509.2	3.0	Yes	No	No	No	Yes	No	Yes	No	No		No		No		2.0
H2AC16	8332	ENST00000357320	NM_003511	ENST00000613174	NM_003511	3.0	Yes	No	No	No	Yes	No	Yes	No	No		No		No		2.0
H2AC17	8336	ENST00000359611	NM_003514	ENST00000359611	NM_003514	3.0	Yes	Yes	No	No	Yes	No	Yes	No	No		No		No		2.0
H2AC6	8334	ENST00000314088	NM_003512.3	ENST00000314088	NM_003512.3	3.0	Yes	No	No	No	Yes	No	Yes	No	No		No		No		2.0
H2BC11	8970	ENST00000339812	NM_021058.3	ENST00000339812	NM_021058.3	3.0	Yes	No	No	No	Yes	No	Yes	No	No		No		No		2.0
H2BC12	85236	ENST00000356950	NM_080593.2	ENST00000356950	NM_080593.2	3.0	Yes	No	No	No	Yes	No	Yes	No	No		No		No		2.0
H2BC17	8348	ENST00000616182	NM_003527.4	ENST00000616182	NM_003527.4	3.0	Yes	No	No	No	Yes	No	Yes	No	No		No		No		2.0
H2BC4	8347	ENST00000314332	NM_003518.3	ENST00000314332	NM_003518.3	3.0	Yes	No	No	No	Yes	No	Yes	No	No		No		No		2.0
H2BC5	3017	ENST00000289316	NM_021063.3	ENST00000289316	NM_021063.3	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
H3-4	8290	ENST00000366696	NM_003493.2	ENST00000366696	NM_003493.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
H3-5	440093	ENST00000340398	NM_001013699.2	ENST00000340398	NM_001013699.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
H3C1	8350	ENST00000357647	NM_003529.2	ENST00000356476	NM_003529.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
H3C10	8357	ENST00000369163	NM_003536.2	ENST00000369163	NM_003536.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
H3C11	8354	ENST00000328488	NM_003533.2	ENST00000616365	NM_003533.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
H3C12	8356	ENST00000359303	NM_003535.2	ENST00000359303	NM_003535.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
H3C13	653604	ENST00000331491	NM_001123375.2	ENST00000331491	NM_001123375.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
H3C14	126961	ENST00000369158	NM_021059.2	ENST00000369158	NM_021059.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
H3C3	8352	ENST00000540144	NM_003531.2	ENST00000612966	NM_003531.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
H3C4	8351	ENST00000356476	NM_003530.4	ENST00000356476	NM_003530.4	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
H3C6	8353	ENST00000360408	NM_003532.2	ENST00000634733	NM_003532.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
H3C7	8968	ENST00000446824	NM_021018.2	ENST00000618052	NM_021018.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
H3C8	8355	ENST00000305910	NM_003534.2	ENST00000614378	NM_003534.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
HDAC4	9759	ENST00000345617	NM_006037.3	ENST00000345617	NM_006037.3	3.0	Yes	Yes	Yes	No	Yes	No	Yes	No	No		No		No		2.0
HDAC7	51564	ENST00000427332	XM_011538481.1	ENST00000427332	XM_011538481.1	3.0	Yes	Yes	No	No	Yes	No	Yes	No	No		No		No		2.0
HIF1A	3091	ENST00000337138	NM_001530.3	ENST00000337138	NM_001530.3	3.0	Yes	Yes	No	No	Yes	No	No	No	Yes	1.0	Yes	oncogene	Yes		1.0
HLA-B	3106	ENST00000412585	NM_005514.6	ENST00000412585	NM_005514.6	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
HOXB13	10481	ENST00000290295	NM_006361.5	ENST00000290295	NM_006361.5	3.0	Yes	Yes	Yes	Yes	Yes	No	No	No	No		No		Yes		2.0
ICOSLG	23308	ENST00000407780	NM_015259.4	ENST00000407780	NM_015259.4	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
IFNGR1	3459	ENST00000367739	NM_000416.2	ENST00000367739	NM_000416.2	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
IGF1	3479	ENST00000307046	NM_001111285.1	ENST00000307046	NM_001111285.1	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
IGF2	3481	ENST00000434045	NM_001127598.1	ENST00000434045	NM_001127598.1	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		Yes		2.0
IKZF3	22806	ENST00000346872	NM_012481.4	ENST00000346872	NM_012481.4	3.0	Yes	Yes	Yes	No	Yes	No	Yes	No	No		No		No		2.0
IL10	3586	ENST00000423557	NM_000572.2	ENST00000423557	NM_000572.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
INHA	3623	ENST00000243786	NM_002191.3	ENST00000243786	NM_002191.3	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
INPP4A	3631	ENST00000074304	NM_001134224.1	ENST00000074304	NM_001134224.1	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
INPPL1	3636	ENST00000298229	NM_001567.3	ENST00000298229	NM_001567.3	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
INSR	3643	ENST00000302850	NM_000208.2	ENST00000302850	NM_000208.2	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
IRF1	3659	ENST00000245414	NM_002198.2	ENST00000245414	NM_002198.2	3.0	Yes	No	Yes	No	Yes	No	Yes	No	No		No		No		2.0
IRF8	3394	ENST00000268638	NM_002163.2	ENST00000268638	NM_002163.2	3.0	Yes	No	Yes	No	Yes	No	Yes	No	No		No		No		2.0
IRS1	3667	ENST00000305123	NM_005544.2	ENST00000305123	NM_005544.2	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
JARID2	3720	ENST00000341776	NM_004973.3	ENST00000341776	NM_004973.3	3.0	Yes	Yes	Yes	No	Yes	No	Yes	No	No		No		No		2.0
KAT6A	7994	ENST00000265713	NM_006766.4	ENST00000265713	NM_006766.4	3.0	Yes	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
KMT2B	9757	ENST00000222270	NM_014727.1	ENST00000420124	NM_014727.1	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
KMT5A	387893	ENST00000330479	NM_020382.3	ENST00000402868	NM_020382.3	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
KNSTRN	90417	ENST00000249776	NM_033286.3	ENST00000249776	NM_033286.3	3.0	Yes	No	No	Yes	Yes	No	No	No	No	2.0	Yes	oncogene	No		1.0
LCK	3932	ENST00000336890	NM_001042771.2	ENST00000336890	NM_001042771.2	3.0	Yes	Yes	No	No	Yes	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
LMO2	4005	ENST00000395833	NM_001142315.1	ENST00000395833	NM_001142315.1	3.0	Yes	Yes	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
LZTR1	8216	ENST00000215739	NM_006767.3	ENST00000646124	NM_006767.3	3.0	Yes	No	Yes	Yes	No	No	No	No	Yes	1.0	Yes	TSG	Yes		1.0
MAFB	9935	ENST00000373313	NM_005461.4	ENST00000373313	NM_005461.4	3.0	Yes	Yes	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
MAPK3	5595	ENST00000263025	NM_002746.2	ENST00000263025	NM_002746.2	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
MAPKAP1	79109	ENST00000265960	NM_001006617.1	ENST00000265960	NM_001006617.1	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
MDC1	9656	ENST00000376406	NM_014641.2	ENST00000376406	NM_014641.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
MECOM	2122	ENST00000468789	NM_001105078.3	ENST00000468789	NM_001105078.3	3.0	Yes	Yes	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
MGA	23269	ENST00000219905	NM_001164273.1	ENST00000219905	NM_001164273.1	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
MLLT10	8028	ENST00000307729	NM_001195626.1	ENST00000307729	NM_001195626.1	3.0	Yes	Yes	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
MSI1	4440	ENST00000257552	NM_002442.3	ENST00000257552	NM_002442.3	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
MST1	4485	ENST00000449682	NM_020998.3	ENST00000449682	NM_020998.3	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
MTAP	4507	ENST00000380172	NM_002451.3	ENST00000644715	NM_002451.3	3.0	Yes	No	Yes	Yes	No	Yes	No	No	No		No		Yes		2.0
MYB	4602					3.0	No	No	No	No	No	Yes	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		
NCOA3	8202	ENST00000371998	NM_181659.2	ENST00000371998	NM_181659.2	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		Yes		2.0
NCSTN	23385	ENST00000294785	NM_015331.2	ENST00000294785	NM_015331.2	3.0	Yes	Yes	No	No	Yes	No	Yes	No	No		No		No		2.0
NEGR1	257194	ENST00000357731	NM_173808.2	ENST00000357731	NM_173808.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
NKX3-1	4824	ENST00000380871	NM_006167.3	ENST00000380871	NM_006167.3	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
NOTCH4	4855	ENST00000375023	NM_004557.3	ENST00000375023	NM_004557.3	3.0	Yes	Yes	Yes	Yes	Yes	No	No	No	No		No		No		2.0
NR4A3	8013	ENST00000395097	NM_006981.3	ENST00000395097	NM_006981.3	3.0	Yes	Yes	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
NTHL1	4913	ENST00000219066	NM_002528.5	ENST00000219066	NM_002528.5	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No	2.0	Yes	TSG	No		1.0
NUF2	83540	ENST00000271452	NM_031423.3	ENST00000271452	NM_031423.3	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
NUP98	4928	ENST00000359171	XM_005252950.1	ENST00000355260	XM_005252950.1	3.0	Yes	Yes	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
NUTM1	256646	ENST00000333756	XM_011521429.1	ENST00000333756	XM_011521429.1	3.0	Yes	No	No	No	No	Yes	No	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
PAK1	5058	ENST00000356341	NM_002576.4	ENST00000356341	NM_002576.4	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
PAK5	57144	ENST00000353224	NM_177990.2	ENST00000353224	NM_177990.2	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
PCBP1	5093	ENST00000303577	NM_006196.3	ENST00000303577	NM_006196.3	3.0	Yes	No	No	No	Yes	No	Yes	No	No	2.0	Yes		No		1.0
PDGFB	5155	ENST00000331163	NM_002608.2	ENST00000331163	NM_002608.2	3.0	Yes	Yes	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
PDPK1	5170	ENST00000342085	NM_002613.4	ENST00000342085	NM_002613.4	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
PGR	5241	ENST00000325455	NM_000926.4	ENST00000325455	NM_000926.4	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		Yes		2.0
PIK3C3	5289	ENST00000262039	NM_002647.2	ENST00000262039	NM_002647.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
PIK3CD	5293	ENST00000377346	NM_005026.3	ENST00000377346	NM_005026.3	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
PIK3R3	8503	ENST00000262741	NM_003629.3	ENST00000262741	NM_003629.3	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
PLCG1	5335	ENST00000373271	NM_182811.1	ENST00000373271	NM_182811.1	3.0	Yes	Yes	No	No	Yes	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
PLK2	10769	ENST00000274289	NM_006622.3	ENST00000274289	NM_006622.3	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
PMAIP1	5366	ENST00000316660	NM_021127.2	ENST00000316660	NM_021127.2	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
PMS1	5378	ENST00000441310	NM_000534.4	ENST00000441310	NM_000534.4	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No	2.0	Yes		No		1.0
PNRC1	10957	ENST00000336032	NM_006813.2	ENST00000336032	NM_006813.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
PPP4R2	151987	ENST00000356692	NM_174907.2	ENST00000356692	NM_174907.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
PRDM14	63978	ENST00000276594	NM_024504.3	ENST00000276594	NM_024504.3	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
PRKD1	5587	ENST00000331968	NM_002742.2	ENST00000331968	NM_002742.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
PTP4A1	7803	ENST00000370651	NM_003463.4	ENST00000626021	NM_003463.4	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
PTPN2	5771	ENST00000309660	NM_002828.3	ENST00000309660	NM_002828.3	3.0	Yes	No	Yes	No	Yes	No	Yes	No	No		No		No		2.0
PTPRD	5789	ENST00000356435	NM_002839.3	ENST00000356435	NM_002839.3	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No	2.0	Yes	TSG	Yes		1.0
PTPRS	5802	ENST00000357368	NM_002850.3	ENST00000587303	NM_002850.3	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
RAB35	11021	ENST00000229340	NM_006861.6	ENST00000229340	NM_006861.6	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
RAC2	5880	ENST00000249071	NM_002872.4	ENST00000249071	NM_002872.4	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
RASA1	5921	ENST00000274376	NM_002890.2	ENST00000274376	NM_002890.2	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		Yes		2.0
RBM15	64783	ENST00000369784	NM_022768.4	ENST00000369784	NM_022768.4	3.0	Yes	Yes	Yes	No	No	No	Yes	No	Yes	1.0	Yes	fusion	Yes		1.0
RECQL	5965	ENST00000421138	NM_002907.3	ENST00000421138	NM_002907.3	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
RHEB	6009	ENST00000262187	NM_005614.3	ENST00000262187	NM_005614.3	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		Yes		2.0
RIT1	6016	ENST00000368323	NM_006912.5	ENST00000368323	NM_006912.5	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		Yes		2.0
RPS6KA4	8986	ENST00000334205	NM_003942.2	ENST00000334205	NM_003942.2	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
RPS6KB2	6199	ENST00000312629	NM_003952.2	ENST00000312629	NM_003952.2	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
RRAGC	64121	ENST00000373001	NM_022157.3	ENST00000373001	NM_022157.3	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
RRAS	6237	ENST00000246792	NM_006270.3	ENST00000246792	NM_006270.3	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
RRAS2	22800	ENST00000256196	NM_012250.5	ENST00000256196	NM_012250.5	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		Yes		2.0
RTEL1	51750	ENST00000360203	NM_001283009.1	ENST00000360203	NM_001283009.1	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
RXRA	6256	ENST00000481739	NM_002957.4	ENST00000481739	NM_002957.4	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
RYBP	23429	ENST00000477973	NM_012234.5	ENST00000477973	NM_012234.5	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
SESN1	27244	ENST00000436639	NM_014454.2	ENST00000436639	NM_014454.2	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
SESN2	83667	ENST00000253063	NM_031459.4	ENST00000253063	NM_031459.4	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
SESN3	143686	ENST00000536441	NM_144665.3	ENST00000536441	NM_144665.3	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
SETDB1	9869	ENST00000271640	NM_001145415.1	ENST00000271640	NM_001145415.1	3.0	Yes	Yes	Yes	Yes	Yes	No	No	No	No	2.0	Yes	oncogene	No		1.0
SH2D1A	4068	ENST00000371139	NM_002351.4	ENST00000371139	NM_002351.4	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
SHOC2	8036	ENST00000369452	NM_007373.3	ENST00000369452	NM_007373.3	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
SHQ1	55164	ENST00000325599	NM_018130.2	ENST00000325599	NM_018130.2	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
SLX4	84464	ENST00000294008	NM_032444.2	ENST00000294008	NM_032444.2	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
SMARCE1	6605	ENST00000348513	NM_003079.4	ENST00000348513	NM_003079.4	3.0	Yes	Yes	Yes	Yes	No	No	No	No	Yes	1.0	Yes	TSG	No		1.0
SMC1A	8243	ENST00000322213	NM_006306.3	ENST00000322213	NM_006306.3	3.0	Yes	No	Yes	No	Yes	No	Yes	No	No	2.0	Yes	TSG	No		1.0
SMC3	9126	ENST00000361804	NM_005445.3	ENST00000361804	NM_005445.3	3.0	Yes	No	Yes	No	Yes	No	Yes	No	No		No		No		2.0
SMYD3	64754	ENST00000388985	NM_001167740.1	ENST00000490107	NM_001167740.1	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
SOS1	6654	ENST00000402219	NM_005633.3	ENST00000402219	NM_005633.3	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
SOX17	64321	ENST00000297316	NM_022454.3	ENST00000297316	NM_022454.3	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
SPRED1	161742	ENST00000299084	NM_152594.2	ENST00000299084	NM_152594.2	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
SS18	6760	ENST00000415083	NM_001007559.2	ENST00000415083	NM_001007559.2	3.0	Yes	Yes	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		1.0
STK19	8859	ENST00000375331	NM_004197.1	ENST00000375331	NM_004197.1	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
STK40	83931	ENST00000373129	NM_032017.1	ENST00000373129	NM_032017.1	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
TAL1	6886	ENST00000294339	NM_001287347.2	ENST00000294339	NM_001287347.2	3.0	Yes	Yes	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
TAP1	6890	ENST00000354258	NM_000593.5	ENST00000354258	NM_000593.5	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
TAP2	6891	ENST00000374899	NM_018833.2	ENST00000383119	NM_018833.2	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
TCL1A	8115	ENST00000402399	NM_001098725.1	ENST00000402399	NM_001098725.1	3.0	Yes	Yes	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
TFE3	7030	ENST00000315869	NM_006521.5	ENST00000315869	NM_006521.5	3.0	Yes	Yes	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
TGFBR1	7046	ENST00000374994	NM_004612.2	ENST00000374994	NM_004612.2	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		No		2.0
TLX1	3195	ENST00000370196	NM_005521.3	ENST00000370196	NM_005521.3	3.0	Yes	Yes	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
TLX3	30012	ENST00000296921	NM_021025.2	ENST00000296921	NM_021025.2	3.0	Yes	Yes	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		1.0
TP53BP1	7158	ENST00000382044	NM_001141980.1	ENST00000382044	NM_001141980.1	3.0	Yes	No	Yes	Yes	Yes	No	No	No	No		No		Yes		2.0
TRAF3	7187	ENST00000392745	NM_003300.3	ENST00000392745	NM_003300.3	3.0	Yes	No	Yes	No	Yes	No	Yes	No	No		No		No		2.0
TRAF5	7188	ENST00000261464	NM_001033910.2	ENST00000261464	NM_001033910.2	3.0	Yes	No	Yes	No	Yes	No	Yes	No	No		No		No		2.0
TYK2	7297	ENST00000264818	NM_003331.4	ENST00000264818	NM_003331.4	3.0	Yes	Yes	No	No	Yes	No	Yes	No	No		No		Yes		2.0
U2AF2	11338	ENST00000308924	NM_007279.2	ENST00000308924	NM_007279.2	3.0	Yes	No	No	No	Yes	No	Yes	No	No		No		No		2.0
UBR5	51366	ENST00000520539	NM_015902.5	ENST00000520539	NM_015902.5	3.0	Yes	Yes	No	No	Yes	No	No	No	Yes	1.0	Yes	oncogene	No		1.0
UPF1	5976	ENST00000262803	NM_002911.3	ENST00000262803	NM_002911.3	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
USP8	9101	ENST00000307179	NM_001128610.2	ENST00000307179	NM_001128610.2	3.0	Yes	Yes	No	Yes	No	No	No	No	Yes	1.0	Yes	oncogene	No		1.0
VTCN1	79679	ENST00000369458	NM_024626.3	ENST00000369458	NM_024626.3	3.0	Yes	No	No	Yes	Yes	No	No	No	No		No		No		2.0
XBP1	7494	ENST00000216037	NM_005080.3	ENST00000216037	NM_005080.3	3.0	Yes	Yes	No	No	Yes	No	Yes	No	No		No		No		2.0
XIAP	331	ENST00000355640	NM_001167.3	ENST00000355640	NM_001167.3	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
YAP1	10413	ENST00000282441	NM_001130145.2	ENST00000282441	NM_001130145.2	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		Yes		2.0
YES1	7525	ENST00000314574	NM_005433.3	ENST00000314574	NM_005433.3	3.0	Yes	Yes	No	Yes	Yes	No	No	No	No		No		No		2.0
ABI1	10006					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
ACTG1	71	ENST00000331925	NM_001199954.1	ENST00000573283	NM_001199954.1	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
ACVR1B	91					2.0	No	No	No	No	No	Yes	No	Yes	No		No		No		
AFDN	4301					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
AFF1	4299					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
AFF4	27125					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
AGO1	26523	ENST00000373204	NM_012199.2	ENST00000373204	NM_012199.2	2.0	Yes	Yes	No	Yes	No	No	No	No	No		No		No		2.0
ALB	213	ENST00000295897	NM_000477.5	ENST00000295897	NM_000477.5	2.0	Yes	No	No	Yes	No	No	No	No	No		No		No		2.0
APLNR	187	ENST00000257254	NM_005161.4	ENST00000257254	NM_005161.4	2.0	Yes	Yes	Yes	Yes	No	No	No	No	No		No		No		2.0
ARFRP1	10139					2.0	No	No	No	No	No	Yes	Yes	No	No		No		No		
ARHGAP26	23092					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
ARHGAP35	2909	ENST00000404338	NM_004491.4	ENST00000404338	NM_004491.4	2.0	Yes	Yes	Yes	Yes	No	No	No	No	No		No		Yes		2.0
ARHGEF12	23365					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
ARHGEF28	64283	ENST00000426542	NM_001177693.1	ENST00000426542	NM_001177693.1	2.0	Yes	Yes	No	No	Yes	No	No	No	No		No		No		2.0
ARID3A	1820	ENST00000263620	NM_005224.2	ENST00000263620	NM_005224.2	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
ARID3B	10620	ENST00000346246	NM_001307939.1	ENST00000346246	NM_001307939.1	2.0	Yes	Yes	No	No	Yes	No	No	No	No		No		No		2.0
ARID3C	138715	ENST00000378909	NM_001017363.1	ENST00000378909	NM_001017363.1	2.0	Yes	No	No	No	Yes	No	No	No	No		No		No		2.0
ARID4A	5926	ENST00000355431	NM_002892.3	ENST00000355431	NM_002892.3	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
ARID4B	51742	ENST00000264183	NM_001206794.1	ENST00000264183	NM_001206794.1	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
ARID5A	10865	ENST00000357485	NM_212481.1	ENST00000357485	NM_212481.1	2.0	Yes	No	No	No	Yes	No	No	No	No		No		No		2.0
ARNT	405					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	No		
ATIC	471					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
ATP6AP1	537	ENST00000369762	NM_001183.5	ENST00000369762	NM_001183.5	2.0	Yes	No	No	No	Yes	No	No	No	No		No		No		2.0
ATP6V1B2	526	ENST00000276390	NM_001693.3	ENST00000276390	NM_001693.3	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
ATXN2	6311	ENST00000377617	NM_002973.3	ENST00000550104	NM_002973.3	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
ATXN7	6314	ENST00000295900	NM_000333.3	ENST00000295900	NM_000333.3	2.0	Yes	Yes	No	Yes	No	No	No	No	No		No		No		2.0
BACH2	60468	ENST00000257749	NM_001170794.1	ENST00000257749	NM_001170794.1	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
BCL11A	53335					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
BCL2L2	599					2.0	No	No	No	No	No	Yes	Yes	No	No		No		No		
BCL3	602					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
BCL7A	605					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
BTG2	7832					2.0	No	No	No	No	No	Yes	Yes	No	No		No		No		
CAMTA1	23261					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
CARS1	833					2.0	No	No	No	No	No	No	Yes	No	Yes		No		No		
CBFA2T3	863					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	Yes		
CD22	933					2.0	No	No	No	No	No	Yes	Yes	No	No		No		No		
CD28	940	ENST00000324106	NM_006139.3	ENST00000324106	NM_006139.3	2.0	Yes	Yes	No	No	Yes	No	No	No	No	2.0	Yes	oncogene	No		1.0
CD70	970					2.0	No	No	No	No	No	Yes	Yes	No	No		No		No		
CD74	972					2.0	No	No	No	No	No	Yes	No	No	Yes	1.0	Yes	oncogene, fusion	No		
CDX2	1045					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	Yes		
CEP43	11116					2.0	No	No	No	No	No	No	Yes	No	Yes		No		No		
CLTC	1213					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
CLTCL1	8218					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
CMTR2	55783	ENST00000338099	NM_001099642.1	ENST00000338099	NM_001099642.1	2.0	Yes	No	Yes	Yes	No	No	No	No	No		No		No		2.0
CNTRL	11064					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
COL1A1	1277					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
CRBN	51185	ENST00000231948	NM_016302.3	ENST00000231948	NM_016302.3	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		Yes		2.0
CREB1	1385	ENST00000432329	NM_134442.3	ENST00000432329	NM_134442.3	2.0	Yes	Yes	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		1.0
CREB3L1	90993					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
CREB3L2	64764					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
CTNNA1	1495					2.0	No	No	No	No	No	Yes	Yes	No	No		No		No		
CTR9	9646	ENST00000361367	NM_014633.4	ENST00000361367	NM_014633.4	2.0	Yes	No	Yes	Yes	No	No	No	No	No		No		No		2.0
CYP19A1	1588	ENST00000260433	NM_000103.3	ENST00000396402	NM_000103.3	2.0	Yes	Yes	No	Yes	No	No	No	No	No		No		No		2.0
DDX10	1662					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
DDX6	1656					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
DNM2	1785					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG	No		
EBF1	1879					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
ECT2L	345930	ENST00000367682	NM_001077706.2	ENST00000367682	NM_001077706.2	2.0	Yes	No	Yes	No	No	No	Yes	No	No	2.0	Yes		No		1.0
EGR1	1958	ENST00000239938	NM_001964.2	ENST00000239938	NM_001964.2	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
ELF4	2000					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	No		
ELL	8178					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
EML4	27436					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
EMSY	56946					2.0	No	No	No	No	No	Yes	Yes	No	No		No		No		
EP400	57634	ENST00000389561	NM_015409.3	ENST00000389561	NM_015409.3	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
EPOR	2057	ENST00000222139	NM_000121.3	ENST00000222139	NM_000121.3	2.0	Yes	Yes	No	No	No	No	Yes	No	No		No		Yes		2.0
EPS15	2060					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
ESCO2	157570	ENST00000305188	NM_001017420.2	ENST00000305188	NM_001017420.2	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
ETAA1	54465	ENST00000272342	NM_019002.3	ENST00000272342	NM_019002.3	2.0	Yes	No	Yes	Yes	No	No	No	No	No		No		No		2.0
EZHIP	340602	ENST00000342995	NM_203407.2	ENST00000342995	NM_203407.2	2.0	Yes	Yes	No	Yes	No	No	No	No	No		No		No		2.0
EZR	7430					2.0	No	No	No	No	No	Yes	No	No	Yes	1.0	Yes	fusion	No		
FANCE	2178					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG	No		
FANCF	2188					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG	No		
FCGR2B	2213					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		
FCRL4	83417					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
FGF10	2255					2.0	No	No	No	No	No	Yes	Yes	No	No		No		No		
FGF14	2259					2.0	No	No	No	No	No	Yes	Yes	No	No		No		No		
FGF23	8074					2.0	No	No	No	No	No	Yes	Yes	No	No		No		No		
FGF6	2251					2.0	No	No	No	No	No	Yes	Yes	No	No		No		No		
FHIT	2272					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
FOXF1	2294	ENST00000262426	NM_001451.2	ENST00000262426	NM_001451.2	2.0	Yes	Yes	Yes	Yes	No	No	No	No	No		No		Yes		2.0
FOXO3	2309					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	Yes		
FOXO4	4303					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	No		
FSTL3	10272					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
FURIN	5045	ENST00000268171	NM_001289823.1	ENST00000268171	NM_001289823.1	2.0	Yes	Yes	No	No	Yes	No	No	No	No		No		No		2.0
FUS	2521					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
GAB1	2549	ENST00000262994	NM_002039.3	ENST00000262994	NM_002039.3	2.0	Yes	Yes	No	Yes	No	No	No	No	No		No		No		2.0
GAB2	9846	ENST00000361507	NM_080491.2	ENST00000361507	NM_080491.2	2.0	Yes	Yes	No	Yes	No	No	No	No	No		No		No		2.0
GAS7	8522					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
GID4	79018					2.0	No	No	No	No	No	Yes	Yes	No	No		No		No		
GPHN	10243					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
GTF2I	2969	ENST00000324896	NM_032999.3	ENST00000573035	NM_032999.3	2.0	Yes	Yes	No	No	Yes	No	No	No	No		No		No		2.0
H1-5	3009	ENST00000331442	NM_005322.2	ENST00000331442	NM_005322.2	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
H2BC8	8339	ENST00000244601	NM_003518	ENST00000541790	NM_003518	2.0	Yes	No	No	No	Yes	No	No	No	No		No		No		2.0
H4C9	8294					2.0	No	No	No	No	No	No	Yes	No	Yes		No		No		
HERPUD1	9709					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
HEY1	23462					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
HIP1	3092					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
HLA-C	3107	ENST00000376228	NM_002117.5	ENST00000376228	NM_002117.5	2.0	Yes	No	Yes	Yes	No	No	No	No	No		No		Yes		2.0
HLF	3131					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
HMGA1	3159					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
HMGA2	8091					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		
HOXA11	3207					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	No		
HOXA13	3209					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
HOXA9	3205					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	No		
HOXC11	3227					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
HOXC13	3229					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
HOXD11	3237					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
HOXD13	3239					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
HSP90AA1	3320					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
HSP90AB1	3326					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
IGH	3492					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
IGK	50802					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
IGL	3535					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
IL21R	50615					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
IL3	3562	ENST00000296870	NM_000588.3	ENST00000296870	NM_000588.3	2.0	Yes	Yes	No	No	No	No	Yes	No	No		No		No		2.0
ITK	3702					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
KBTBD4	55709	ENST00000395288	NM_016506.5	ENST00000395288	NM_016506.5	2.0	Yes	No	No	Yes	No	No	No	No	No		No		No		2.0
KDSR	2531					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
KIF5B	3799					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
KLF5	688	ENST00000377687	NM_001730.4	ENST00000377687	NM_001730.4	2.0	Yes	Yes	No	Yes	No	No	No	No	No		No		No		2.0
KLHL6	89857					2.0	No	No	No	No	No	Yes	Yes	No	No		No		No		
KSR2	283455	ENST00000339824		ENST00000339824		2.0	Yes	Yes	No	No	Yes	No	No	No	No		No		No		2.0
LASP1	3927					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
LEF1	51176					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, TSG	No		
LPP	4026					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
LRP1B	53353					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG	Yes	LRP1B is a putative tumor suppressor and a member of the low-density lipoprotein (LDL) receptor family. The LDL receptor family have roles related to clearance of extracellular ligand and are proposed to be involved in extracellular signal transduction. silencing and down-expression of LRP1B as been observed in renal cell carcinoma and thyroid cancer. Further Deletion of LRP1B has been associated with chemotherapy resistance in high-grade serous cancers.	
LTB	4050	ENST00000376117	NM_002341.1	ENST00000376117	NM_002341.1	2.0	Yes	Yes	Yes	No	Yes	No	No	No	No		No		No		2.0
LYL1	4066					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
MAD2L2	10459	ENST00000235310	NM_001127325.1	ENST00000235310	NM_001127325.1	2.0	Yes	Yes	Yes	Yes	No	No	No	No	No		No		No		2.0
MGAM	8972	ENST00000549489	NM_004668.2	ENST00000549489	NM_004668.2	2.0	Yes	Yes	No	No	Yes	No	No	No	No		No		No		2.0
MLF1	4291					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
MLLT3	4300					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
MLLT6	4302					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
MN1	4330					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		
MOB3B	79817	ENST00000262244	NM_024761.4	ENST00000262244	NM_024761.4	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
MPEG1	219972	ENST00000361050	NM_001039396.1	ENST00000361050	NM_001039396.1	2.0	Yes	No	No	No	Yes	No	No	No	No		No		No		2.0
MRTFA	57591					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	No		
MSN	4478					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
MUC1	4582					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
MYH11	4629					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
MYH9	4627					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
NADK	65220	ENST00000341426	NM_001198993.1	ENST00000341426	NM_001198993.1	2.0	Yes	Yes	No	Yes	No	No	No	No	No		No		No		2.0
NCOA2	10499					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		
NDRG1	10397					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
NFE2	4778	ENST00000312156	NM_001136023.2	ENST00000312156	NM_001136023.2	2.0	Yes	Yes	No	No	Yes	No	No	No	No		No		No		2.0
NFKB2	4791					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	No		
NIN	51199					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
NRG1	3084	ENST00000405005	NM_013964.3	ENST00000405005	NM_013964.3	2.0	Yes	Yes	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	Yes		1.0
NUMA1	4926					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
NUP214	8021					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
NUTM2A	728118					2.0	No	No	No	No	No	No	Yes	No	Yes		No		No		
PAFAH1B2	5049					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
PAX3	5077					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
PAX7	5081					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
PAX8	7849	ENST00000263334	NM_003466.3	ENST00000348715	NM_003466.3	2.0	Yes	Yes	No	No	No	No	No	No	Yes	1.0	Yes	fusion	Yes	PAX8 is one of nine transcription factors within the PAX gene family. It has been observed to be expressed during embryonic development however expression attenuates after development in all but a few tissues. Research has indicated that over-expression of PAX proteins in general are not an initiating event in tumorgenesis however they may facilitate malignant development. PAX8 is expressed in 80-96% of all High-grade serous carcinomas (HGSC) and is commonly used as a marker for the disease. In addition PAX8 has become a useful biomarker for differentiating between mullerian mucinous and non-mullerian tumors. PAX8 has also been associated with neoplasms in the kidney and thyroid.	1.0
PBX1	5087					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
PCM1	5108					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
PDE4DIP	9659					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
PDK1	5163					2.0	No	No	No	No	No	Yes	Yes	No	No		No		No		
PDS5B	23047	ENST00000315596	NM_015032.3	ENST00000315596	NM_015032.3	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
PER1	5187					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
PGBD5	79605	ENST00000525115	NM_001258311.1	ENST00000525115	NM_001258311.1	2.0	Yes	Yes	No	Yes	No	No	No	No	No		No		No		2.0
PICALM	8301					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
PIGA	5277	ENST00000333590	NM_002641.3	ENST00000333590	NM_002641.3	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
PLAG1	5324					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
PML	5371					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	Yes	The PML-RARA fusion is the result of a recurrent, balanced translocation between chromosomes 15 and 17, denoted as t(15;17)(q22;q12), and a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA (all-trans retinoic acid) in APL patients harboring the PML-RARA fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising. However, newly discovered mutations in the B2 domain of PML have started to show conferred resistance to ATRA in these patients.	
POU2AF1	5450					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
PPP2R2A	5520	ENST00000380737	NM_002717.3	ENST00000380737	NM_002717.3	2.0	Yes	No	Yes	No	No	Yes	No	No	No		No		No		2.0
PRDM16	63976					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
PRKACA	5566	ENST00000308677	NM_002730.3	ENST00000308677	NM_002730.3	2.0	Yes	Yes	No	No	No	No	No	No	Yes	1.0	Yes	oncogene	Yes	PRKACA has been studied in breast cancer and has been found to mediate resistance to HER2 targeted therapies. It has also been found to contain a mutation hotspot that contributes to neoplastic behavior in neuroendocrine cancers. In hepatocellular fibrolamellar carcinoma (FL-HCC), the fusion DNAJB1 to PRKACA is suggested to be a diagnostic marker for this rare subtype of HCC. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity.	1.0
PRRX1	5396					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
PSIP1	11168					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
PTPN1	5770	ENST00000371621	NM_001278618.1	ENST00000371621	NM_001278618.1	2.0	Yes	Yes	Yes	No	Yes	No	No	No	No		No		No		2.0
PTPRO	5800					2.0	No	No	No	No	No	Yes	Yes	No	No		No		No		
QKI	9444					2.0	No	No	No	No	No	Yes	No	No	Yes	1.0	Yes	oncogene, TSG	No		
RABEP1	9135					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
RAP1GDS1	5910					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
RELN	5649	ENST00000428762	NM_005045.3	ENST00000428762	NM_005045.3	2.0	Yes	No	No	No	No	No	Yes	No	No		No		No		2.0
REST	5978	ENST00000309042	NM_001193508.1	ENST00000309042	NM_001193508.1	2.0	Yes	No	Yes	Yes	No	No	No	No	No		No		No		2.0
RHOH	399					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
RNF213	57674					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
ROBO1	6091	ENST00000464233	NM_002941.3	ENST00000464233	NM_002941.3	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
RPL22	6146					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
RPN1	6184					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
RSPO2	340419					2.0	No	No	No	No	No	Yes	No	No	Yes	1.0	Yes	TSG, fusion	No		
SAMHD1	25939	ENST00000262878	NM_015474.3	ENST00000646673	NM_015474.3	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
SCG5	6447	ENST00000300175	NM_001144757.1	ENST00000300175	NM_001144757.1	2.0	Yes	Yes	No	Yes	No	No	No	No	No		No		No		2.0
SDC4	6385					2.0	No	No	No	No	No	Yes	No	No	Yes	1.0	Yes	fusion	No		
SERPINB3	6317	ENST00000283752	NM_006919.2	ENST00000283752	NM_006919.2	2.0	Yes	Yes	Yes	Yes	No	No	No	No	No		No		No		2.0
SERPINB4	6318	ENST00000341074	NM_002974.3	ENST00000341074	NM_002974.3	2.0	Yes	No	No	Yes	No	No	No	No	No		No		No		2.0
SET	6418					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
SETD1A	9739	ENST00000262519	NM_014712.2	ENST00000262519	NM_014712.2	2.0	Yes	Yes	No	No	Yes	No	No	No	No		No		No		2.0
SETD1B	23067	ENST00000604567	XM_005253858.3	ENST00000604567	XM_005253858.3	2.0	Yes	No	No	No	Yes	No	No	No	No	2.0	Yes	TSG	No		1.0
SETD3	84193	ENST00000331768	NM_032233.2	ENST00000331768	NM_032233.2	2.0	Yes	No	No	No	Yes	No	No	No	No		No		No		2.0
SETD4	54093	ENST00000332131	NM_017438.4	ENST00000332131	NM_017438.4	2.0	Yes	No	No	No	Yes	No	No	No	No		No		No		2.0
SETD5	55209	ENST00000402198	NM_001080517.2	ENST00000402198	NM_001080517.2	2.0	Yes	No	No	No	Yes	No	No	No	No		No		No		2.0
SETD6	79918	ENST00000219315	NM_001160305.1	ENST00000219315	NM_001160305.1	2.0	Yes	No	No	No	Yes	No	No	No	No		No		No		2.0
SETD7	80854	ENST00000274031	NM_001306199.1	ENST00000274031	NM_001306199.1	2.0	Yes	No	No	No	Yes	No	No	No	No		No		No		2.0
SETDB2	83852	ENST00000354234	NM_031915.2	ENST00000317257	NM_031915.2	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
SH3GL1	6455					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
SLC34A2	10568					2.0	No	No	No	No	No	Yes	No	No	Yes	1.0	Yes	TSG, fusion	No		
SLFN11	91607	ENST00000308377	NM_001104587.1	ENST00000308377	NM_001104587.1	2.0	Yes	No	Yes	Yes	No	No	No	No	No		No		Yes		2.0
SMARCA2	6595	ENST00000349721	NM_001289396.1	ENST00000349721	NM_001289396.1	2.0	Yes	No	Yes	Yes	No	No	No	No	No		No		No		2.0
SMG1	23049	ENST00000446231	NM_015092.4	ENST00000446231	NM_015092.4	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
SOCS3	9021	ENST00000330871	NM_003955.4	ENST00000330871	NM_003955.4	2.0	Yes	No	Yes	No	No	No	Yes	No	No		No		No		2.0
SP140	11262	ENST00000392045	NM_007237.4	ENST00000392045	NM_007237.4	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
SPRTN	83932	ENST00000295050	NM_032018.6	ENST00000295050	NM_032018.6	2.0	Yes	No	Yes	Yes	No	No	No	No	No		No		No		2.0
SRSF3	6428					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
SSX1	6756					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		
SSX2	6757					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		
SSX4	6759					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		
STAG1	10274	ENST00000383202	NM_005862.2	ENST00000383202	NM_005862.2	2.0	Yes	No	Yes	No	Yes	No	No	No	No	2.0	Yes	TSG	No		1.0
TAF15	8148					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
TAL2	6887					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
TET3	200424	ENST00000409262	NM_144993	ENST00000409262	NM_144993	2.0	Yes	No	Yes	No	Yes	No	No	No	No		No		No		2.0
TFG	10342					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
TNFRSF17	608					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	Yes		
TPM3	7170					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
TPM4	7171					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
TRA	6955					2.0	Yes	Yes	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		1.0
TRB	6957					2.0	Yes	Yes	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		1.0
TRD	6964					2.0	Yes	Yes	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		1.0
TRG	6965					2.0	Yes	Yes	No	No	No	No	Yes	No	No		No		No		2.0
TRIM24	8805					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, TSG, fusion	No		
TRIP11	9321					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
TRIP13	9319	ENST00000166345	NM_004237.3	ENST00000166345	NM_004237.3	2.0	Yes	Yes	Yes	Yes	No	No	No	No	No		No		No		2.0
USP6	9098					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
VAV1	7409	ENST00000602142	NM_005428.3	ENST00000602142	NM_005428.3	2.0	Yes	Yes	No	No	Yes	No	No	No	No	2.0	Yes	fusion	No		1.0
VAV2	7410	ENST00000371850	NM_001134398.1	ENST00000371850	NM_001134398.1	2.0	Yes	Yes	No	No	Yes	No	No	No	No		No		No		2.0
WIF1	11197	ENST00000286574	NM_007191.4	ENST00000286574	NM_007191.4	2.0	Yes	No	Yes	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		1.0
ZBTB16	7704					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	TSG, fusion	No		
ZMYM2	7750					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
ZNF217	7764					2.0	No	No	No	No	No	Yes	Yes	No	No		No		No		
ZNF384	171017					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	fusion	No		
ZNF521	25925					2.0	No	No	No	No	No	No	Yes	No	Yes	1.0	Yes	oncogene, fusion	No		
ZNF703	80139					2.0	No	No	No	No	No	Yes	Yes	No	No		No		No		
ZNRF3	84133	ENST00000544604	NM_001206998.1	ENST00000544604	NM_001206998.1	2.0	Yes	No	Yes	Yes	No	No	No	No	No	2.0	Yes	TSG	No		1.0
ACKR3	57007					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		
ACSL3	2181					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
ACSL6	23305					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	fusion	No		
ACTB	60					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
ACVR2A	92					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
ADGRA2	25960					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
AFF3	3899					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		
AJUBA	84962	ENST00000262713	NM_032876.5	ENST00000262713	NM_032876.5	1.0	Yes	No	Yes	No	No	No	No	No	No		No		No		2.0
APH1A	51107					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
APOBEC3B	9582					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, TSG	No		
ASMTL	8623					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
ASPSCR1	79058					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
ATG5	9474					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
ATP1A1	476					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, TSG	No		
ATP2B3	492					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
BAX	581					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
BCL9L	283149					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, TSG	No		
BRD3	8019					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		
BRSK1	84446					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
BTLA	151888					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
BUB1B	701					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
CACNA1D	776					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene	No		
CAD	790					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
CANT1	124583					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
CBLB	868					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	Yes		
CBLC	23624					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, TSG	Yes		
CCDC6	8030					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
CCN6	8838					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
CCNB1IP1	57820					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
CCNB3	85417	ENST00000276014	NM_033031.2	ENST00000276014	NM_033031.2	1.0	Yes	Yes	No	No	No	No	No	No	No		No		No		2.0
CCT6B	10693					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
CD36	948					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
CDH11	1009					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
CHCHD7	79145					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
CHD2	1106					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	TSG	No		
CHD4	1108					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene	No		
CHIC2	26511					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	fusion	No		
CHN1	1123					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
CILK1	22858					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
CKS1B	1163					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
CLIP1	6249					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
CLP1	10978					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	fusion	No		
CNBP	7555					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
CNOT3	4849					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
COL2A1	1280					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
CPS1	1373					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
CRTC1	23373					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		
CRTC3	64784					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
CSF1	1435					1.0	No	No	No	No	No	No	Yes	No	No		No		Yes		
CUL4A	8451					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
CYP17A1	1586					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
DAZAP1	26528	ENST00000233078	NM_018959.3	ENST00000233078	NM_018959.3	1.0	Yes	No	No	No	No	No	No	No	No		No		No		2.0
DCTN1	1639					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
DDB2	1643					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, TSG	No		
DDR1	780					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
DDX4	54514	ENST00000505374	NM_024415.2	ENST00000505374	NM_024415.2	1.0	Yes	Yes	No	No	No	No	No	No	No		No		No		2.0
DDX41	51428	ENST00000507955	NM_016222.2	ENST00000330503	NM_016222.2	1.0	Yes	No	Yes	No	No	No	No	No	No		No		Yes		2.0
DDX5	1655					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		
DKK1	22943	ENST00000373970	NM_012242.2	ENST00000373970	NM_012242.2	1.0	Yes	No	No	No	No	No	No	No	No		No		Yes		2.0
DKK2	27123	ENST00000285311	NM_014421.2	ENST00000285311	NM_014421.2	1.0	Yes	No	No	No	No	No	No	No	No		No		No		2.0
DKK3	27122	ENST00000326932	NM_001018057.1	ENST00000326932	NM_001018057.1	1.0	Yes	No	No	No	No	No	No	No	No		No		No		2.0
DKK4	27121	ENST00000220812	NM_014420.2	ENST00000220812	NM_014420.2	1.0	Yes	No	No	No	No	No	No	No	No		No		No		2.0
DUSP2	1844					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
DUSP9	1852					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
EIF3E	3646					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
ELK4	2005					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		
ELN	2006					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	fusion	No		
ELP2	55250					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
EPHB4	2050					1.0	No	No	No	No	No	Yes	No	No	No		No		Yes		
ERC1	23085					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
ETS1	2113					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
EXOSC6	118460					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
EXT1	2131					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
EXT2	2132					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
FAF1	11124					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
FAT4	79633					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
FBXO31	79791					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
FES	2242					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, TSG	No		
FGF12	2257					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
FIP1L1	81608					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
FLYWCH1	84256					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
FNBP1	23048					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	fusion	No		
FRS2	10818					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
GABRA6	2559					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
GADD45B	4616					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
GATA4	2626					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
GATA6	2627					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
GMPS	8833					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	fusion	No		
GOLGA5	9950					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
GOPC	57120					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
GPC3	2719					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, TSG	No		
GRM3	2913					1.0	No	No	No	No	No	Yes	No	No	No	2.0	Yes	oncogene	No		
GTSE1	51512					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
H3C15	333932	ENST00000331491	NM_001005464.2	ENST00000331491	NM_001005464.2	1.0	Yes	No	No	No	No	No	No	No	No		No		No		2.0
H3P6	440926	ENST00000316450		ENST00000369387		1.0	Yes	No	No	No	No	No	No	No	No		No		No		2.0
HIRA	7290					1.0	No	No	No	No	Yes	No	No	No	No		No		No		
HNRNPA2B1	3181					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		
HOOK3	84376					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
HOXA3	3200					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
HSD3B1	3283					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
IKBKB	3551					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene	No		
IKZF2	22807					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
IL2	3558					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
IL6ST	3572					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene	No		
INPP5D	3635					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
IRF2	3660					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
IRS4	8471					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, TSG	No		
JAZF1	221895					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	fusion	No		
KAT6B	23522					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
KCNJ5	3762					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene	No		
KDM2B	84678					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
KDM4C	23081					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
KEL	3792					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
KLF2	10365	ENST00000248071	NM_016270.2	ENST00000248071	NM_016270.2	1.0	Yes	No	Yes	No	No	No	No	No	No		No		No		2.0
KLF3	51274	ENST00000261438	NM_016531.5	ENST00000261438	NM_016531.5	1.0	Yes	No	Yes	No	No	No	No	No	No		No		No		2.0
KLF6	1316					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
KLK2	3817					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
KNL1	57082					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
KTN1	3895					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
LARP4B	23185	ENST00000316157	NM_015155.2	ENST00000316157	NM_015155.2	1.0	Yes	No	No	No	No	No	No	No	No	2.0	Yes	TSG	No		1.0
LCP1	3936					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	fusion	No		
LIFR	3977					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
LMNA	4000					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
LRIG3	121227					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
LRP5	4041	ENST00000294304	NM_001291902.1	ENST00000294304	NM_001291902.1	1.0	Yes	Yes	Yes	No	No	No	No	No	No		No		No		2.0
LRP6	4040	ENST00000261349	NM_002336.2	ENST00000261349	NM_002336.2	1.0	Yes	Yes	No	No	No	No	No	No	No		No		No		2.0
LRRK2	120892					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
LTK	4058					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
MAGED1	9500					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
MAML2	84441					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		
MAP3K6	9064					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
MAP3K7	6885					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
MBD6	114785	ENST00000355673	NM_052897.3	ENST00000355673	NM_052897.3	1.0	Yes	No	Yes	No	No	No	No	No	No		No		No		2.0
MDS2	259283					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	fusion	No		
MEF2C	4208					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
MEF2D	4209	ENST00000348159	NM_005920.3	ENST00000348159	NM_005920.3	1.0	Yes	Yes	No	No	No	No	No	No	No		No		Yes		2.0
MERTK	10461					1.0	No	No	No	No	No	Yes	No	No	No		No		Yes		
MIB1	57534					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
MIDEAS	91748	ENST00000286523	NM_001043318.2	ENST00000286523	NM_001043318.2	1.0	Yes	No	Yes	No	No	No	No	No	No		No		No		2.0
MKI67	4288					1.0	No	No	No	No	No	No	Yes	No	No		No		Yes		
MKNK1	8569					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
MLLT11	10962					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
MNX1	3110					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	fusion	No		
MTCP1	4515					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		
MYO18A	399687					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
MYO5A	4644					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
NAB2	4665					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
NACA	4666					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	fusion	No		
NBEAP1	606					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
NCOA1	8648					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
NCOA4	8031					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
NFATC2	4773					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		
NFIB	4781					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
NFKBIE	4794					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
NOD1	10392					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
NONO	4841					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
NUTM2B	729262					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
OLIG2	10215					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		
OMD	4958					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	fusion	No		
PAG1	55824					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
PAK3	5063					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
PARP2	10038					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
PARP3	10039					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
PASK	23178					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
PATZ1	23598					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
PC	5091					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
PCLO	27445					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
PCSK7	9159					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
PDCD11	22984					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
PHF1	5252					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
PIK3C2B	5287					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
POLQ	10721					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, TSG	No		
POU5F1	5460					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, fusion	Yes		
PPFIBP1	8496					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
PPP1CB	5500					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
PRCC	5546					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
PRF1	5551					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
PRKDC	5591					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
PRSS1	5644	ENST00000311737	NM_002769.4	ENST00000311737	NM_002769.4	1.0	Yes	No	No	No	No	No	No	No	No		No		No		2.0
PRSS8	5652					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
PTK6	5753					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, TSG	No		
PTK7	5754					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
PTPN13	5783					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
PTPN6	5777					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	TSG	Yes		
PTPRB	5787					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	Yes		
PTPRC	5788					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
PTPRK	5796					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
RALGDS	5900					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	fusion	No		
RANBP2	5903					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
RASGEF1A	221002					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
RMI2	116028					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
RNF217-AS1	7955					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
RPL10	6134					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
RPL5	6125					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
RSPO3	84870					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		
RUNX2	860					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
S1PR2	9294					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
SALL4	57167					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene	No		
SBDS	51119					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
SEC31A	22872					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
SEPTIN5	5413					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
SEPTIN6	23157					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
SEPTIN9	10801					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
SERP2	387923					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
SFPQ	6421					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
SFRP1	6422	ENST00000220772	NM_003012.4	ENST00000220772	NM_003012.4	1.0	Yes	No	Yes	No	No	No	No	No	No		No		No		2.0
SFRP2	6423	ENST00000274063	NM_003013.2	ENST00000274063	NM_003013.2	1.0	Yes	Yes	Yes	No	No	No	No	No	No		No		No		2.0
SFRP4	6424					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
SIX1	6495					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene	No		
SLC1A2	6506					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
SLC45A3	85414					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
SMARCA1	6594					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
SNCAIP	9627					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
SND1	27044					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		
SNX29	92017					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	fusion	No		
SOCS2	8835					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
SOX10	6663					1.0	No	No	No	No	No	No	Yes	No	No		No		Yes		
SS18L1	26039					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
STAT1	6772	ENST00000361099	NM_007315.3	ENST00000361099	NM_007315.3	1.0	Yes	No	No	No	No	No	No	No	No		No		Yes		2.0
STAT2	6773	ENST00000314128	NM_005419.3	ENST00000314128	NM_005419.3	1.0	Yes	No	No	No	No	No	No	No	No		No		No		2.0
STAT4	6775					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
STIL	6491					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		
STRN	6801					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
TAF1	6872					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
TCEA1	6917					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
TCF12	6938					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
TCL1B	9623	ENST00000340722	NM_004918.3	ENST00000340722	NM_004918.3	1.0	Yes	Yes	No	No	No	No	No	No	No		No		No		2.0
TEC	7006					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	oncogene, fusion	No		
TERC	7012					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
TFEB	7942					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		
TFPT	29844					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	fusion	No		
TFRC	7037					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	fusion	No		
TIPARP	25976					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
TLE1	7088	ENST00000376499	NM_001303103.1	ENST00000376499	NM_001303103.1	1.0	Yes	No	No	No	No	No	No	No	No		No		No		2.0
TLE2	7089	ENST00000262953	NM_003260.4	ENST00000262953	NM_003260.4	1.0	Yes	No	No	No	No	No	No	No	No		No		No		2.0
TLE3	7090	ENST00000558939	NM_005078.3	ENST00000558939	NM_005078.3	1.0	Yes	No	No	No	No	No	No	No	No		No		No		2.0
TLE4	7091	ENST00000376552	NM_007005.4	ENST00000376552	NM_007005.4	1.0	Yes	No	No	No	No	No	No	No	No		No		No		2.0
TLL2	7093					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
TMEM30A	55754					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
TMSB4XP8	7117					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
TNFRSF11A	8792					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
TPR	7175					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
TRIM27	5987					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene, fusion	No		
TRIM33	51592					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
TRRAP	8295					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene	No		
TTL	150465					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
TUSC3	7991					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
TYRO3	7301					1.0	No	No	No	No	No	Yes	No	No	No		No		No		
WAS	7454					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	oncogene	No		
WDCP	80304					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	fusion	No		
WDR90	197335					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
WRN	7486					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
XPA	7507					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
XPC	7508					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG	No		
YPEL5	51646					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
YWHAE	7531					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
YY1	7528	ENST00000262238	NM_003403.4	ENST00000262238	NM_003403.4	1.0	Yes	Yes	No	No	No	No	No	No	No		No		No		2.0
YY1AP1	55249					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
ZBTB20	26137	ENST00000474710	NM_001164342.2	ENST00000474710	NM_001164342.2	1.0	Yes	Yes	Yes	No	No	No	No	No	No		No		No		2.0
ZBTB7A	51341					1.0	No	No	No	No	Yes	No	No	No	No		No		No		
ZFP36L1	677	ENST00000336440	NM_001244698.1	ENST00000336440	NM_001244698.1	1.0	Yes	No	Yes	No	No	No	No	No	No		No		No		2.0
ZMYM3	9203					1.0	No	No	No	No	No	No	Yes	No	No	2.0	Yes	TSG	No		
ZNF24	7572					1.0	No	No	No	No	No	No	Yes	No	No		No		No		
ZNF331	55422					1.0	No	No	No	No	No	No	No	No	Yes	1.0	Yes	TSG, fusion	No		
ZNF750	79755	ENST00000269394	NM_024702.2	ENST00000269394	NM_024702.2	1.0	Yes	No	Yes	No	No	No	No	No	No		No		No		2.0
A1CF	29974							Yes	No							2.0	Yes	oncogene	No		
AKAP9	10142							No	No							2.0	Yes	fusion	No		
ALDH2	217							No	No							2.0	Yes	fusion	No		
ANK1	286							No	No							2.0	Yes		No		
ARHGAP5	394							Yes	No							2.0	Yes	oncogene	No		
ARHGEF10	9639							No	Yes							2.0	Yes	TSG	No		
ARHGEF10L	55160							No	Yes							2.0	Yes	TSG	No		
BAZ1A	11177							No	Yes							2.0	Yes	TSG	No		
BCL2L12	83596							Yes	No							2.0	Yes	oncogene	No		
BCLAF1	9774							No	No							2.0	Yes		No		
BIRC6	57448							Yes	No							2.0	Yes	oncogene, fusion	No		
BMP5	653							No	No							2.0	Yes		No		
C15orf65	145788							No	No							2.0	Yes	fusion	No		
CARS	833							No	Yes							1.0	Yes	TSG, fusion	No		
CASP3	836							No	Yes							2.0	Yes	TSG	No		
CASP9	842							No	Yes							2.0	Yes	TSG	No		
CCNC	892							No	Yes							2.0	Yes	TSG	No		
CCR4	1233							Yes	No							2.0	Yes	oncogene	No		
CCR7	1236							Yes	No							2.0	Yes	oncogene	No		
CD209	30835							No	No							2.0	Yes		No		
CDH10	1008							No	Yes							2.0	Yes	TSG	No		
CDH17	1015							Yes	No							2.0	Yes	oncogene	No		
CEP89	84902							No	No							2.0	Yes	fusion	No		
CHST11	50515							Yes	No							2.0	Yes	oncogene, fusion	No		
CNBD1	168975							No	No							2.0	Yes		No		
CNTNAP2	26047							No	Yes							2.0	Yes	TSG	No		
COL3A1	1281							No	No							2.0	Yes	fusion	No		
COX6C	1345							No	No							2.0	Yes	fusion	No		
CPEB3	22849							No	Yes							2.0	Yes	TSG	No		
CRNKL1	51340							No	No							2.0	Yes		No		
CSMD3	114788							No	Yes							2.0	Yes	TSG	No		
CTNNA2	1496							Yes	No							2.0	Yes	oncogene	No		
CTNND1	1500							No	No							2.0	Yes		No		
CTNND2	1501							Yes	No							2.0	Yes	oncogene	No		
CYP2C8	1558							No	No							2.0	Yes		No		
DCAF12L2	340578							No	No							2.0	Yes		No		
DCC	1630							No	No							2.0	Yes		Yes		
DGCR8	54487							Yes	No							2.0	Yes	oncogene	No		
DUX4L1	22947							No	No							2.0	Yes	fusion	No		
BIVM-ERCC5	100533467							No	Yes							1.0	Yes	TSG	No		
FAM131B	9715							No	No							2.0	Yes	fusion	No		
FAM135B	51059							No	No							2.0	Yes		No		
FAM47C	442444							No	No							2.0	Yes		No		
FAT3	120114							No	No							2.0	Yes		No		
FBLN2	2199							No	Yes							2.0	Yes	TSG	No		
FEN1	2237							No	Yes							2.0	Yes	TSG	No		
FGFR1OP	11116							No	No							1.0	Yes	fusion	No		
FKBP9	11328							No	No							2.0	Yes		No		
FLNA	2316							No	No							2.0	Yes		No		
FOXR1	283150							Yes	No							2.0	Yes	oncogene, fusion	No		
GPC5	2262							No	Yes							2.0	Yes	TSG	No		
H3F3A	3020							Yes	No							1.0	Yes	oncogene	No		
H3F3B	3021							Yes	No							1.0	Yes	oncogene	No		
HIST1H3B	8358							Yes	No							1.0	Yes	oncogene	No		
HIST1H4I	8294							No	No							1.0	Yes	fusion	No		
HMGN2P46	283651							No	No							2.0	Yes	fusion	No		
IGF2BP2	10644							No	Yes							2.0	Yes	TSG	No		
ISX	91464							No	No							2.0	Yes		No		
ITGAV	3685							No	No							2.0	Yes		No		
KAT7	11143							Yes	No							2.0	Yes	oncogene	No		
KIAA1549	57670							No	No							2.0	Yes	fusion	No		
LEPROTL1	23484							No	Yes							2.0	Yes	TSG	No		
LHFPL6	10186							No	No							2.0	Yes	fusion	No		
LSM14A	26065							No	No							2.0	Yes	fusion	No		
MACC1	346389							Yes	No							2.0	Yes	oncogene	No		
MALAT1	378938							Yes	Yes							2.0	Yes	oncogene, TSG, fusion	No		
MB21D2	151963							No	No							2.0	Yes		No		
MGMT	4255							No	Yes							2.0	Yes	TSG	Yes		
MUC16	94025							Yes	No							2.0	Yes	oncogene	No		
MUC4	4585							Yes	No							2.0	Yes	oncogene	No		
N4BP2	55728							No	Yes							2.0	Yes	TSG	No		
NBEA	26960							No	No							2.0	Yes		No		
NCKIPSD	51517							No	No							2.0	Yes	fusion	No		
NUTM2D	728130							No	No							1.0	Yes	fusion	No		
PABPC1	26986							Yes	Yes							2.0	Yes	oncogene, TSG	No		
POLG	5428							No	Yes							2.0	Yes	TSG	No		
PRDM2	7799							No	Yes							2.0	Yes	TSG	No		
PRKCB	5579							No	No							2.0	Yes		Yes		
PRPF40B	25766							No	No							2.0	Yes		No		
PWWP2A	114825							No	No							2.0	Yes	fusion	No		
RAD17	5884							No	Yes							2.0	Yes	TSG	No		
RFWD3	55159							No	Yes							2.0	Yes	TSG	No		
RGPD3	653489							No	No							2.0	Yes		No		
RGS7	6000							No	No							2.0	Yes		No		
ROBO2	6092							No	Yes							2.0	Yes	TSG	No		
S100A7	6278							No	No							2.0	Yes	fusion	No		
SEPT5	5413							No	No							2.0	Yes	fusion	No		
SEPT6	23157							No	No							2.0	Yes	fusion	No		
SEPT9	10801							No	No							2.0	Yes	fusion	No		
SHTN1	57698							No	No							2.0	Yes	fusion	No		
SIRPA	140885							No	Yes							2.0	Yes	TSG	No		
SIX2	10736							Yes	No							2.0	Yes	oncogene	No		
SKI	6497							Yes	No							2.0	Yes	oncogene	No		
SOX21	11166							No	Yes							2.0	Yes	TSG	No		
SPECC1	92521							No	No							2.0	Yes	fusion	No		
SRGAP3	9901							No	No							2.0	Yes	fusion	No		
THRAP3	9967							No	No							2.0	Yes	fusion	No		
TNC	3371							Yes	No							2.0	Yes	oncogene	No		
USP44	84101							No	Yes							2.0	Yes	TSG	No		
VTI1A	143187							No	No							2.0	Yes	fusion	No		
WNK2	65268							No	Yes							2.0	Yes	TSG	No		
ZCCHC8	55596							No	No							2.0	Yes	fusion	No		
ZEB1	6935							Yes	No							2.0	Yes	oncogene	Yes		
ZNF429	353088							No	No							2.0	Yes		No		
ZNF479	90827							No	No							2.0	Yes		No		
TTF1	7270																No		Yes		
ACTA1	58																No		Yes		
ACTL6A	86																No		Yes		
AEBP1	165																No		Yes		
ALCAM	214																No		Yes		
BIRC5	332																No		Yes		
AREG	374																No		Yes		
ASCL1	429																No		Yes		
ASNS	440																No		Yes		
ASS1	445																No		Yes		
BLK	640																No		Yes		
CD44	960																No		Yes		
CDK2	1017																No		Yes		
CDK5	1020																No		Yes		
CDK9	1025																No		Yes		
CTAG1B	1485																No		Yes		
CCN2	1490																No		Yes		
CYP2D6	1565																No		Yes		
DBI	1622																No		Yes		
GADD45A	1647																No		Yes		
DEFA1	1667																No		Yes		
NQO1	1728																No		Yes		
DPYD	1806																No		Yes		
DRD5	1816																No		Yes		
DUSP6	1848																No		Yes		
EFNA2	1943																No		Yes		
EGF	1950																No		Yes		
EIF4EBP1	1978																No		Yes		
EPHB2	2048																No		Yes		
ERCC1	2067																No		Yes		
EREG	2069																No		Yes		
ETS2	2114																No		Yes		
PTK2B	2185																No		Yes		
FCGR2A	2212																No		Yes		
FCGR3A	2214																No		Yes		
FGF2	2247																No		Yes		
FGF13	2258																No		Yes		
FOXC2	2303																No		Yes		
FNTB	2342																No		Yes		
FOS	2353																No		Yes		
GAS6	2621																No		Yes		
B4GALT1	2683																No		Yes		
GSTP1	2950																No		Yes		
HDAC2	3066																No		Yes		
HLA-DRA	3122																No		Yes		
HMOX1	3162																No		Yes		
HOXD8	3234																No		Yes		
HSPA5	3309																No		Yes		
HSPB1	3315																No		Yes		
IL2RB	3560																No		Yes		
IL6	3569																No		Yes		
CXCL10	3627																No		Yes		
KRT18	3875																No		Yes		
LAG3	3902																No		Yes		
STMN1	3925																No		Yes		
LEPR	3953																No		Yes		
TACSTD2	4070																No		Yes		
MMP2	4313																No		Yes		
MMP9	4318																No		Yes		
MTHFR	4524																No		Yes		
NEDD9	4739																No		Yes		
NT5E	4907																No		Yes		
PCNA	5111																No		Yes		
ABCB1	5243																No		Yes		
PLK1	5347																No		Yes		
PRKAA2	5563																No		Yes		
MAP2K7	5609																No		Yes		
PRPS1	5631																No		Yes		
PSMB8	5696																No		Yes		
PSMD4	5710																No		Yes		
PTGS2	5743																No		Yes		
PTPN12	5782																No		Yes		
PTPRF	5792																No		Yes		
RAD23B	5887																No		Yes		
RELA	5970																No		Yes		
RPS6	6194																No		Yes		
RRM1	6240																No		Yes		
RRM2	6241																No		Yes		
SCN8A	6334																No		Yes		
CX3CL1	6376																No		Yes		
SULT1E1	6783																No		Yes		
TCF19	6941																No		Yes		
NR2F2	7026																No		Yes		
TFF3	7033																No		Yes		
TGFA	7039																No		Yes		
TGFBR3	7049																No		Yes		
THBS2	7058																No		Yes		
TIMP1	7076																No		Yes		
TOP2A	7153																No		Yes		
TPT1	7178																No		Yes		
TSPYL1	7259																No		Yes		
TYMS	7298																No		Yes		
UGT1A	7361																No		Yes		
VEGFC	7424																No		Yes		
WEE1	7465																No		Yes		
WNT11	7481																No		Yes		
XRCC1	7515																No		Yes		
ABCC3	8714																No		Yes		
CFLAR	8837																No		Yes		
PROM1	8842																No		Yes		
ALDH1A2	8854																No		Yes		
SPHK1	8877																No		Yes		
MBD4	8930																No		Yes		
PTTG1	9232																No		Yes		
ABCG2	9429																No		Yes		
KIF23	9493																No		Yes		
HDAC9	9734																No		Yes		
CUL7	9820																No		Yes		
SPRY2	10253																No		Yes		
MAEA	10296																No		Yes		
TUBB3	10381																No		Yes		
AGR2	10551																No		Yes		
SLCO1B1	10599																No		Yes		
DLL3	10683																No		Yes		
STAG3	10734																No		Yes		
HSPH1	10808																No		Yes		
TLK2	11011																No		Yes		
PTP4A3	11156																No		Yes		
ZHX2	22882																No		Yes		
SIRT1	23411																No		Yes		
PPP1R15A	23645																No		Yes		
PDCD4	27250																No		Yes		
MAGEH1	28986																No		Yes		
TBK1	29110																No		Yes		
CTAG2	30848																No		Yes		
FOXP3	50943																No		Yes		
RSF1	51773																No		Yes		
ROBO4	54538																No		Yes		
UGT1A1	54658																No		Yes		
NUDT15	55270																No		Yes		
DDX43	55510																No		Yes		
CHD7	55636																No		Yes		
WDR12	55759																No		Yes		
PBK	55872																No		Yes		
POLE4	56655																No		Yes		
CIP2A	57650																No		Yes		
PAPPA2	60676																No		Yes		
PBLD	64081																No		Yes		
BIRC7	79444																No		Yes	BIRC7 encodes the protein Livin which is a member of the inhibitor of apoptosis protein (IAP) family. Livin consists of a single baculoviral IAP repeat domain (BIR) and a RING domian at the C-terminus. The protein inhibits apoptosis by inhibiting proteolytic activation of capsases.  Overexpression of Livin has been observed in a variety of cancers including lung, colon, and prostate compared to most normal adult tissues and has been proposed as a putative therapeutic target.	
NECTIN4	81607																No		Yes		
HAVCR2	84868																No		Yes		
ABCC10	89845																No		Yes		
IL33	90865																No		Yes		
RCSD1	92241																No		Yes		
NAPRT	93100																No		Yes		
VPS37A	137492																No		Yes		
PXDNL	137902																No		Yes		
DGKH	160851																No		Yes		
RABL3	285282																No		Yes		
ATXN1L	342371																No		Yes		
MIR21	406991																No		Yes		
MIR218-1	407000																No		Yes		
ECSCR	641700																No		Yes		
KLLN	100144748																No		Yes		
DUX4	100288687																No		Yes		
PRNCR1	101867536																No		Yes		
